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General Introduction

The three main tasks o f the clinician are diagnosis, prognosis and treatment. O f these, 
diagnosis is by far the most important, for upon it the success o f the other two depends.
The opening gambit of this thesis comes from John A Ryle’s book “The natural 
history of disease.” Published in 1948, this book sets out Ryle’s observations on 
disease states and firmly places diagnosis at the heart of medical practice. Nothing 
much has changed in 50 years. Medical students still learn to recognise the 
presenting symptoms of a large number of diseases. They learn which additional 
tests to perform in order to become more certain about the presence of disease. 
After diagnosis has been established, prognosis can be considered and options for 
treatment are discussed with the patient.
For a doctor to decide which presenting features and which additional tests to rely 
on, he must know their diagnostic value. Diagnostic research studies the value of 
diagnostic tests. There have been major changes in the principles of diagnostic 
research over the past half century. In 1957, Ledley and Lusted first proposed the 
use of Bayes’ Theorem in diagnosis and diagnostic research. Nowadays, this 
method is still frequently taught in courses in epidemiology and evidence based 
medicine [Sacket et al., 1997]. More recently, logistic regression analysis and ROC- 
curves were put forward as the proper framework for the evaluation of diagnostic 
tests [Van der Schouw et al., 1995; Miettinen, 1998]. A common property of these 
methods is their dependence on a clear definition of the disease at issue. In other 
words, a gold standard to provide the ultimate proof of the presence of disease must 
be available. The research that led to the present thesis was initiated to explore the 
principles of diagnostic research in ill-defined diseases, which are characterised by 
the absence of a gold standard test.
Two aspects must be considered in the evaluation of diagnostic tests. The first 
aspect deals with the validity of the test: to what extent does the test result correlate 
with that of the gold standard? The other aspect is the reproducibility of the test: to 
what extent does the test result correlate with subsequent measurements? As ill- 
defined diseases are characterised by the absence of a gold standard, validity 
research is troublesome in these instances. Study of a test’s reproducibility does not 
require a gold standard. Therefore, this thesis addresses issues of reproducibility 
before issues of validity. The second part of the thesis deals with the methods of 
quantifying the reproducibility of a diagnostic test.
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The third part of this thesis discusses the issue of validity. The traditional methods 
of validity research are described, ranging from calculation of sensitivity and 
specificity to regression analysis. These methods can still be used in the absence of a 
gold standard, provided there is an acceptable “silver standard” or reference test. In 
addition, neural network analysis is presented as a novel technique to study the 
value of diagnostic tests. Even with the use of sophisticated neural network analysis, 
however, a “silver standard” cannot replace the gold one. As the principles of 
diagnostic research flow from the adopted concept of disease, the last chapter of this 
thesis addresses the problem of a missing gold standard from a philosophical point 
of view and questions the leading role of diagnosis in medical practice.
Throughout this thesis, many examples from the field of urology are presented. In 
particular, patients with lower urinary tract symptoms (LUTS) are the subjects of 
these examples. LUTS were previously referred to as benign prostatic hyperplasia 
and prostatism. The causes and presentation of LUTS are diverse, and although 
several tests are available for the evaluation of patients the value of many of these 
tests is not well understood. This lack of knowledge is often ascribed to the absence 
of a clear definition of the disease. In fact, many experts have repeatedly stressed the 
need for a case definition of LUTS [Oishi et al., 1998]. In the absence of such a 
definition, the diagnosis of patients with LUTS will benefit from an increased 
understanding of the principles of diagnostic research. In order to introduce the 
patients with LUTS, the first part of this thesis describes the aetiology and 
prevalence of this ill-defined disease and the methods to diagnose and treat the 
patients with it.
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Part 1
Lower Urinary Tract Symptoms

Chapter 1
The prostate is a walnut-sized gland that forms part of the male reproductive 
system. It is involved in the production, storage, and ejaculation of seminal fluid. 
The prostate is located in front of the rectum and just below the bladder, 
surrounding the prostatic urethra (figure 1.1). It is partly muscular and partly 
glandular, with ducts opening into the prostatic urethra. The prostate is made up of 
two lateral lobes and a small median lobe. As a man matures, the prostate goes 
through two main periods of growth. The first period occurs early in puberty when 
the prostate doubles in size. Around age 25, the gland begins to grow again. This 
second growth phase is due to benign prostatic hyperplasia (BPH). It is estimated 
that 50% of the male population has histological BPH when they are 51 to 60 years 
old. This percentage rises to 90% in the ninth decade of life [Berry et al., 1984].
Figure 1.1 The prostate and its surrounding organs
* CIBA-GEIGY Corporation Pharmaceuticals Division, 1989
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BPH often leads to macroscopically detectable benign prostatic enlargement (BPE). 
The enlarged gland may start to press against the urethra like a clamp on a garden 
hose, obstructing the bladder outlet. This effect is called static bladder outlet 
obstruction (BOO). Obstruction can also result from increased tonicity of smooth 
muscle cells within the prostate and the bladder neck. This constriction of the 
bladder outlet is thought to be reversible and is therefore called dynamic BOO. 
Both static and dynamic BOO increase the urethral resistance, requiring more 
powerful contractions of the bladder to empty. As a result, the bladder wall 
becomes thicker and irritable, leading to frequent urge to urinate even when the 
bladder contains only small amounts of urine. In addition, the detrusor muscle 
weakens and at some point fails to overcome the pressure inside the urethra. 
Consequently, urine remains in the bladder. The narrowing of the urethra and the 
partial emptying of the bladder can cause many symptoms, including polyuria, 
nocturia, reduced size and force of the urinary stream, dribbling, hesitancy, and 
intermittency. These symptoms are called lower urinary tract symptoms (LUTS). 
LUTS were previously called BPH and prostatism. These names, however, 
mistakenly suggest the prostate to be the only organ involved, whereas up to one 
third of the patients have other causes of LUTS, such as cardiovascular problems, 
detrusor instability, and detrusor underactivity [Abrams, 1994a].
Figure 1.2 shows the various aspects of voiding dysfunction and their overlap. BPH 
not always leads to BPE, BPE not always obstructs the urethra, and BOO not 
always causes LUTS. Conversely, LUTS also occurs in the absence of BOO, and 
BOO need not be based on BPE. Many tests are used in the diagnosis of patients 
with LUTS. Routine work-up usually includes medical history, standardised 
symptom evaluation, physical examination with digital rectal examination, serum 
and urine analyses, prostate size measurement, uroflowmetry, and determination of 
post-void residual urine (PVR). Pressure-flow studies (PFS) are considered optional.
Symptom score questionnaires are used to standardise the documentation of the pa­
tient’s symptoms, and to assess the amount of bother these symptoms cause. 
Through the years, several scoring systems have been developed, all roughly asking 
the same questions [Boyarski et al., 1977; Madsen and Iversen, 1983; Barry et al., 
1992]. The International Prostate Symptom Score (IPSS) has been adopted by the 
World Health Organisation as first choice questionnaire.
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Benign Prostatic Lower Urinary Tract
Enlargement Symptoms
Bladder Outlet 
Obstruction
Figure 1.2 The model shows the three main features o f voiding dysfunction and their 
overlap.
Urinalysis is used to evaluate renal function and to detect urinary tract infections. 
Digital rectal examination of the prostate and serum PSA level determination are 
crude initial tests to detect or to rule out prostate cancer. Transrectal or 
transabdominal ultrasound offer a detailed image of the prostate. Ultrasound is also 
useful to estimate the volume of the prostate more accurately.
Uroflowmetry electronically records the strength of the urinary flow throughout the 
course of micturition. Maximum urinary flow rate (Qmax) and voided volume are 
the most informative uroflow variables. After cessation of voiding, the amount of 
PVR is measured using ultrasound.
PFS quantify the urethral resistance by measuring detrusor pressure and urinary 
flow rate simultaneously. High pressure with low flow indicates high urethral 
resistance and is suggestive of BOO. Alternatively, low pressure with low flow 
indicates bladder dysfunction. PFS are the gold standard to identify BOO [Schäfer 
et al., 1989; Abrams, 1994b]. Nevertheless, PFS are often considered too invasive, 
time-consuming and expensive to be routinely used.
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If BOO is established as the cause of LUTS, three treatment categories are 
available: watchful waiting, pharmacological therapy, and instrumental therapy. 
Watchful waiting can be offered to any patient presenting with minimal to mild 
complaints of LUTS. Especially if fear of prostate cancer was the main reason for 
seeking medical care, watchful waiting is an attractive option. Regular control visits 
can be scheduled should the patient want to, although there is no medical rationale 
for such visits. Alternatively, the patient returns when symptoms increase.
Two pharmacological pathways interfere with prostate growth and functioning. 
Firstly, in the presence of the enzyme 5a-reductase, testosterone is transformed into 
the biologically more active dihydrotestosterone (DHT). D H T controls prostate 
growth. Regression of prostate size in men with BPH can be achieved by 
pharmacological inhibition of 5a-reductase. Secondly, adrenergic nerves determine 
smooth muscle tone inside the prostate and bladder neck by stimulating post-synaptic 
^-adrenoceptors. Increased smooth muscle tone can cause dynamic BOO. Selective 
^-adrenoceptor antagonists can reduce LUTS and improve urinary flow rates, by 
relaxation of the bladder outlet. This treatment is currently the first choice medical 
therapy for symptoms suggestive of BOO. Several a-blocking agents are available, 
with only small differences in objective and subjective response of patients. In 
addition to 5a-reductase inhibitors and ^-adrenoceptor antagonists, phytotherapeutic 
agents are gaining popularity, although their effects have never been properly studied.
Instrumental treatment of the prostate is indicated if watchful waiting and 
pharmacological therapy are insufficient to improve the condition of the patient. 
Open surgery is required if the prostate is extremely large (>100 grams). 
Transurethral resection of the prostate (TURP) is the “gold standard” surgical 
treatment for men with moderately enlarged prostates. TURP endoscopically 
removes abundant prostate tissue. Possible side effects include incontinence and 
retrograde ejaculation. TURP is also associated with minimal peri-operative 
mortality. Because of the morbidity and mortality associated with TURP and the 
need for general or spinal anaesthesia, a number of minimally invasive technologies 
have emerged, some of which are coming into increasing use. Transurethral 
vaporisation of the prostate uses a high-energy electric source to vaporise prostate 
tissue. Compared to TURP, the advantages of the vaporisation procedure are no 
significant bleeding and shorter hospitalisation. Laser technology is used to cut out
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or destroy the prostate tissue. Laser is also considered to control bleeding and to 
decrease the amount of time required for healing. Nevertheless, it is seldom used, as 
clinical outcome proves disappointing. Transurethral Microwave Thermotherapy 
(TUMT) uses microwave energy to heat the prostate tissue through a catheter 
positioned transurethrally. The microwaves destroy a number of cells with heat 
resulting in a gradual shrinkage of the prostate, thus relieving the obstruction of the 
bladder outlet. TUM T is performed in an outpatient session requiring neither 
general nor local anaesthesia. Subjective response after TUM T is comparable with 
response after TURP. Therefore, TUM T is an attractive alternative to TURP for 
patients who prefer minimally invasive treatment and for patients who are poor 
surgical candidates. In transurethral needle ablation (TUNA), a needle applies the 
necessary heat instead of microwaves. Transurethral incision of the prostate (TUIP) 
is occasionally performed in patients with small prostates. An incision is made in 
the prostate tissue to enlarge the opening of the bladder outlet. This procedure is 
also performed on an ambulatory basis. Finally, some almost redundant treatments 
include balloon dilation of the prostatic urethra and placement of prostate stents 
that stretch open the narrowed urethral passage through the prostate gland.
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Chapter 2  Prevalence of lower urinary tract 
symptoms: the Boxmeer study
Introduction
Lower urinary tract symptoms (LUTS) are among the most common conditions 
affecting elderly men. As the community ages, the prevalence of LUTS further 
increases. Valid estimates of the population prevalence of LUTS are essential to 
understanding the magnitude of the problem and to anticipating on future health 
care expenditures. It is estimated that 50% of the male population has histological 
benign prostatic hyperplasia (BPH) when they are 51 to 60 years old. This 
percentage rises to 90% in the ninth decade of life [Berry et al., 1984]. Not all cases 
of BPH are symptomatic, however, and not everyone with LUTS has BPH. Thus, 
the estimated prevalence of histological BPH is likely to be different from the 
prevalence of symptoms. Furthermore, the number of men experiencing symptoms 
may be much higher than the number seeking medical help. Patients may be 
reluctant to visit a doctor out of embarrassment, fear of malignancies, and 
unawareness of minimally invasive treatment options. Thus, hospital-based studies 
are also likely to produce biased prevalence estimates of LUTS. A special committee 
of the World Health Organisation sponsored International Consultation on BPH 
therefore expressed the need for population-based epidemiological data on LUTS 
[Oishi et al., 1998].
While LUTS do not kill, they can be major contributors to a reduced quality of life 
(QoL). The range of activities in which patients with LUTS and their spouses are 
involved is often restricted. Possibly, the reduction in QoL urges the patient to seek 
medical attention, while the presence of urinary symptoms is accepted as part of the 
normal ageing process. Previous studies paid little attention to the relation between 
symptoms and QoL and to the relation between symptoms and health care seeking 
behaviour. In addition, the awareness of the spouses of the urinary symptoms 
perceived by their husbands received little attention.
23
Certain questions regarding the epidemiology of LUTS remain unanswered. How 
prevalent are LUTS in the community and can an age-trend be detected? To what 
extent does LUTS influence the patient’s quality of life? How many men visit 
health care professionals for their symptoms and how many of them use prostate- 
related medication? Are spouses aware of the presence of LUTS? An international, 
population-based, multi-centre study has been established in four countries (The 
Netherlands, France, United Kingdom, and Korea) to study the epidemiology of 
urological conditions, using a common approach in different international settings 
[Boyle et al., 1998]. In this chapter, we present descriptive statistics on LUTS from 
the Dutch part of this study.
Methods
Recruitment of subjects, employing a random selection mechanism that aims to 
provide a representative sample of the population, was conducted in 1998 in the 
municipality of Boxmeer. Boxmeer has a population of approximately 20,000 and 
is located in the southeastern part of the Netherlands. Men aged 40-79 years were 
enrolled in the study. The number of men in this age range is 4,067 (Central 
Bureau of Statistics, 1997). In the Netherlands, there exists a near perfect 
municipality basic administration system. Using this system, the local government 
of Boxmeer provided demographic data from 1,771 male inhabitants. More men 
were sampled in the higher age ranges, as older men are of particular interest in this 
study on LUTS. As the distribution of age in the sample does not reflect the age 
distribution in the source population, a stratified estimator was used to estimate the 
prevalence of LUTS. A stratified estimator is a weighted sum of the prevalence 
estimates of each separate age stratum, with the weights of the strata reflecting the 
difference between the age distributions of the sample and the population. All 
selected men received an invitation letter with an self-administered questionnaire 
and a pre-posted return envelope. The invitation letter explained the goal of the 
study as “to estimate the occurrence o f urological symptoms and their effect on quality o f 
life.” In case of non-response to the postal questionnaire, a telephone interview was 
conducted. If someone did not want to participate, a limited number of questions 
was asked to assess possible differential non-response. Participants had to 
understand the Dutch language and to be capable of completing the questionnaire.
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To document the prevalence of LUTS, the World Health Organisation has adopted 
the International Prostate Symptom Score (IPSS) [Barry et al., 1992]. The IPSS 
grades the presence of seven symptoms related to bladder emptying and storage on 
a severity scale of 0-5 (see the appendix of this chapter). Total symptom scores are 
categorised as mild (0-7), moderate (8-19) and severe (20-35). The IPSS does not 
grade all possible symptoms of voiding dysfunction. For the purpose of our study, 
six questions related to urinary symptoms were therefore added. These questions 
concerned frequency of micturition, dribbling, difficulty to start voiding, reduction 
in size and force of the urinary stream compared to age 20, pain or a burning 
sensation during voiding and ability to postpone voiding.
Information on health care seeking behaviour was collected by asking about doctor 
visits in the past six months and about the use of prostate-related medication. We 
asked the spouses “i f  their partner ever mentioned urinary problems or i f  they ever 
noticed he had urinary problems.” In addition, we asked the spouses to complete the 
IPSS. This latter information can help to assess whether the IPSS is a useful 
measure of prostate related symptoms.
Two internationally accepted and validated questionnaires were used to measure 
the subject’s quality of life (see the appendix of this chapter). The BPH Impact 
Index (BII) measures disease specific QoL on a severity scale from 0-13 [Barry et 
al., 1995]. Total scores are categorised into three classes indicating decreasing QoL, 
namely 0-3, 4-6 and 7-13. Generic quality of life was measured with the SF-12 
questionnaire [Ware et al., 1996]. This 12-item health survey has been used 
extensively in the assessment of medical treatments. From the SF-12, a physical 
component score (PCS) and a mental component score (MCS) are constructed. For 
ease in interpretation, original scores were reverse-scaled so that higher PCS and 
MCS indicated worse condition. Scores are compared and interpreted in relation to 
standard benchmarks, namely a population mean of 50 and standard deviation of 
10 [Gandeket al., 1998].
Results
Twelve-hundred-and-thirty-three men completed the questionnaire (a response of 
70%). The brief non-response questionnaire revealed that non-responders reported
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somewhat less symptoms than responders did. Median IPSS among non-responders 
was one compared to two among responders. The results presented herein apply to 
the 1,233 responders.
Four percent of all men reported severe symptoms, 17% had moderate symptoms, 
and 79% had no or only mild symptoms. The corresponding percentages in 
women were the same. Figure 2.1 shows the prevalence of LUTS in successive age 
categories. Ten percent of men aged 40-49 reported moderate to severe symptoms 
(IPSS > 7) compared to 21% of men aged 50-59, 33% of men aged 60-69 and 
44% of men over 70. The Spearman coefficient of correlation between age and 
IPSS was 0.32 (p = 0.00).
100%
80%
ts
ÏT  60%
¡Uo
0
20%
0%
Figure 2.1 Prevalence o f lower urinary tract symptoms measured with the IPSS 
according to age
Table 2.1 shows the distribution of the separate IPSS symptoms and the six 
additional symptoms used in this study. Dribbling, reduced force of the urinary 
stream since age 20, and difficulty to postpone voiding appeared the three most 
prevalent symptoms.
□  mild symptoms (0-7) □  moderate symptoms (8-19) □  severe symptoms (20-35)
40-49 50-59 60-69
age category (years)
70-79
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Table 2.1 Age standardised percentage distribution o f symptom scores in 1233 men
Symptom
Score
0 1 2 3 4 5 missing
Incomplete emptying* 74 15 4 2 2 2 1
Revoid within two hours* 45 36 7 5 2 3 1
Intermittency* 65 21 6 4 2 2 1
Urgency* 68 18 4 3 3 3 1
Weak stream* 56 23 6 4 4 6 1
Straining* 79 13 3 2 1 1 1
Nocturia* 39 46 10 3 1 0 1
Hesitancy 66 30 3 1 0 - 1
Frequency 41 51 6 1 - - 1
Time able to postpone voiding 33 37 18 9 1 1 1
Diminution of stream since age 20 30 31 24 11 3 - 1
Dribbling 22 65 5 7 1 - 1
Dysuria 76 21 3 0 0 - 1
The specific questions are printed in the appendix o f this chapter.
Percentages are rounded o ff to the nearest integer and therefore do not always add up to 100%. 
* Symptoms present on the International Prostate Symptom Score
O n asking “i f  their partner ever mentioned urinary problems or i f  they ever noticed he 
had urinary problems", 21% of the spouses answered affirmatively. This figure 
corresponds to the number of men reporting moderate to severe LUTS (IPSS > 7). 
Nevertheless, 40% of the women whose partner reported moderate to severe 
symptoms, was not aware of the presence of urinary problems. Ten percent of the 
spouses of men who reported no or only mild symptoms claimed that their 
husbands in fact did have urinary problems. In conclusion, 83% of the pairs agreed 
upon the presence of symptoms.
Figure 2.2 shows the relation between disease-specific QoL measured with the BII 
and the presence of LUTS. Reduction in disease specific QoL was almost 
exclusively seen in men with severe symptoms, although 30% of these men still 
reported excellent disease specific QoL. Overall, 93% of the men reported excellent 
disease-specific QoL.
The relation between LUTS and generic QoL was less pronounced than that 
between LUTS and disease-specific QoL. Mean PCS increased from 49 with no or 
mild symptoms to 53 with moderate symptoms and 55 with severe symptoms (p =
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0.00). Mean MCS increased from 47 to 49 and 51 between the same IPSS 
categories (p = 0.00). These figures must be interpreted in relation to standard 
benchmarks, i.e., a mean of 50 and a standard deviation of 10. Spearman 
correlation coefficients of the IPSS with the PCS and the MCS were 0.3 and 0.2, 
respectively (p = 0.00).
□  BII 0-3 □  BII 4-6 □  BII 7-13
100%
80%
sstc
ub 60% s
i  4 0 % -
cre
p
20%
0% H— ---------  1------------------- --------- --------- --------- --------- --------- --------- --------- —
0-7 8-19 20-35
International prostate symptom score
Figure 2.2 Disease specific quality o f life measured with the BPH Impact Index 
(BII) according to the presence o f LUTS
Seven percent of all men went to see a doctor because of LUTS. Six percent of these 
patients were prescribed prostate-related medication (a-receptor antagonists or 5a- 
reductase inhibitors). A rough estimation shows that 0.4% (7% * 6%) of all men 
between 40-79 years uses prostate related medication. Health care seeking 
behaviour was related to the severity of symptoms. The percentage of men visiting a 
doctor with LUTS increased from 2% among men with no or mild symptoms, to 
24% among men with moderate symptoms and 27% among men with severe 
symptoms. The equivalent figures with decreasing disease specific QoL were 3%, 
24%, and 70%.
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Discussion
This study in a Dutch community shows that a fifth of all Dutch men between 40­
79 years have moderate to severe LUTS (IPSS > 7). This high prevalence of LUTS 
occurs across all ages, but particularly in older age groups. Previous reports confirm 
a high prevalence of urinary symptoms [Chute et al., 1993; Sagnier et al., 1994; 
Bosch et al., 1995; Hunter et al., 1996]. Overall, prevalence of moderate to severe 
symptoms in these studies ranged between 14% and 34%. Figure 2.3 shows 
prevalence estimates from these studies according to age.
........ Bosch [1995]
--------Chute [1993]
--------Hunter [1996]
— Sagnier [1994] 
-------- Sonke [present]
age (years)
Figure 2.3 Prevalence o f moderate to severe symptoms in previous studies according 
to age
W ith the exception of French men in the study by Sagnier et al., the estimated 
prevalences in these studies are in the same general range. Methodological 
differences, such as the sampling method, differing age categories, wording of 
specific questions, and cultural differences in the perception of symptoms may 
account for the variation in study results [Badia et al., 1997; Witjes et al., 1997a]. 
Garraway and colleagues published an often-cited paper in 1991. The authors 
reported a prevalence of 25% for “BPH”, defined by a prostate size > 20 grams in
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the presence of symptoms and/or maximum urinary flow rate < 1 5  ml/s without 
evidence of malignancy. The prevalence increased with age from 14% for men aged 
40-49 years to 43% for men aged 60-69 years. As this study did not use the IPSS to 
define LUTS, comparison with other reports is difficult.
The most commonly reported urinary symptoms are dribbling, reduced size and 
force of the urinary stream and urgency. These symptoms are very common, with 
little increase in prevalence over the years (results not shown). This finding suggests 
that the cause of these symptoms is not related to BOO or bladder hypo- 
contractility. Alternatively, the specific questions may not have been stated in 
sufficient detail to distinguish between pathological and physiological symptoms. 
For instance, almost every man occasionally experiences some dribbling. Owing to 
their high prevalence, these symptoms vary little across patients and are thus not 
suitable to identify specific pathology. Therefore, these symptoms are not part of 
the IPSS. Nevertheless, they can be disabling for a patient and it is important that a 
physician recognises them in a patient with LUTS.
It is remarkable that the prevalence of moderate to severe symptoms, as measured 
with the IPSS is the same in men and women. Despite the worldwide use in 
urological practice of this questionnaire, apparently most of the symptoms listed are 
not prostate specific. Previous studies found similar high symptom scores in women 
[Lepor and Machi, 1993; Madersbacher et al., 1999].
In general, spouses are well aware of their husband’s urinary condition. The 17% 
discordance between the reported symptoms and the spouses’ awareness of these 
symptoms can be attributed to several causes. Firstly, the concerning questions were 
not phrased identically for men and women. Whereas men were administered an 
extensive questionnaire, the spouses were asked a single question about the 
awareness of urinary symptoms. The answer of the man and his partner need not 
refer to the same concept. This problem is inherent to any questionnaire, no matter 
how well it is constructed and validated. Secondly, it is possible that the man 
experiences a symptom, for instance nocturia, differently from his partner. Possibly, 
only one of the couple finds nocturnal visits to the toilet worth mentioning, while 
the other has accepted this habit as a part of “daily” routine. Thirdly, a lack of 
communication can be responsible for the partner’s unawareness of the symptoms 
her husband experiences.
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Although LUTS are common in a Dutch male population, the impact of symptoms 
on generic QoL is negligible. Population-based studies in the United Kingdom, 
Japan, the United States, France, and Scotland showed comparable results [Hunter 
et al., 1995; Girman et al., 1998]. As expected, the correlation between LUTS and 
disease-specific QoL was larger than between LUTS and generic QoL. One 
explanation for these findings is that a generic health questionnaire such as the SF- 
12 is not sensitive enough to detect small differences between subjects in QoL. 
Another explanation involves the so-called response shift. This concept describes 
how patients accommodate to disease by changing their internal standards, values 
and conceptualisation of QoL [Daltroy et al., 1999]. A third explanation for the 
absence of a strong relation between symptoms and generic QoL is that the 
presence of symptoms does not mean that patients suffer from these symptoms. 
The main reason to visit a doctor is probably to reduce the effect of symptoms on 
daily activities. Therefore, the lack of correlation between symptoms and generic 
QoL may also explain why a substantial number of men with moderate or severe 
symptoms did not seek medical attention: their social lives need not be affected by 
the symptoms.
The number of men with LUTS is much higher than the number seeking medical 
care. Some men may still be reluctant to talk about their voiding problems while 
others may be unaware of minimally invasive treatment options. The threshold to 
seek medical care may decrease through public information. As a result, more men 
will visit a doctor to discuss their urinary problems. The other side of this coin, 
however, is that a number of men who considered their urinary condition as a part 
of the normal ageing process start to feel ill, and for that reason demand treatment. 
The consequent cost to society of these additional treatments must be attributed to 
the unwanted integration of a normal ageing process within the realm of medicine. 
Therefore, we must be reluctant to try to persuade men with voiding symptoms of 
the fact that their symptoms can be “treated”.
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Appendix
The International Prostate Symptom Score ( 1 - 7 )  and the additional questions o f this study (8 - 1 3 )
Never
About 1 
time in 5
About 1 
time in 3
About 1 
time in 2
About 2 
times in 3
Almost
always
1. Over the past month, how often have you had a feeling of 
not emptying your bladder completely after you finished 
urinating?
□ □ □ □ □ □
2. Over the past month, how often have you had to urinate 
again less than two hours after you finished urinating?
□ □ □ □ □ □
3. Over the past month, how often have you found you 
stopped and started again several times when you 
urinated?
□ □ □ □ □ □
4. Over the past month, how often have you found it difficult to 
hold back urinating after you have felt the need?
□ □ □ □ □ □
5. Over the past month, how often have you noticed a 
reduction in the strength and force of your urinary stream?
□ □ □ □ □ □
6. Over the past month, how often have you had to push or 
strain to begin urination?
□ □ □ □ □ □
None 1 time 2 times 3 times 4 times >5 times
7. Over the past month, how many times did you most 
typically get up to urinate from the time you went to bed at 
night until the time you got up in the morning?
□ □ □ □ □
Not at all
A few 
seconds
About 15 
seconds
About 30 
seconds
A minute 
or more
8. During the past month, how long have you most commonly 
had to wait at the toilet before urine starts to come out?
□ □ □ □ □
1 - 4 times 
a day
5 - 7 times 
a day
8 - 1 2  times 
a day
>13 times 
a day
9. During the past month, about how many times did you 
urinate from the time you got up in the morning until the 
time you went to bed at night?
□ □ □ □
1 hour or 
more
About 30 
minutes
About 15 
minutes
A few 
minutes
Less than 
1 minute
< 10 
seconds
10. During the past month, once you got the urge to urinate, 
how long could you usually wait comfortably before going to 
the bathroom?
□ □ □ □ □ □
No
impairment
Minimal
impairment
Mild
impairment
Moderate
impairment
Severe
impairment
11. How would you describe the size and force of your urinary 
stream compared to when you were 20 years old?
□ □ □ □ □
Never A few 
drops
Wait to 
finish
Dribble in 
underwear
Require
protection
12. When you feel that you have finished an episode of 
urination do you continue to dribble urine?
□ □ □ □ □
None of 
the time
A little of 
the time
Some o f the 
time
Most o f the 
time
All o f the 
time
13. In the past year, how often, on average, have you had a 
painful or burning feeling during urination?
□ □ □ □ □
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The Benign Prostatic Hyperplasia Impact Index (BII)
None Only a little Some A lot
1. Over the past month, how much physical 
discomfort did any urinary problem cause 
you?
□ □ □ □
2. Over the past month, how much did you 
worry about your health because o f any 
urinary problem?
□ □ □ □
Not at all 
bothersome
Bothers me 
a little
Bothers 
me some
Bothers me 
a lot
3. Overall, how bothersome has any trouble with 
urination been during the past month?
□ □ □ □
None of the 
time
A little o f the 
time
Some of 
the time
Most o f the 
time
All o fthe  
time
4. Over the past month, how much of the time 
has any urinary problem kept you from doing 
the kinds of things you would usually do?
□ □ □ □ □
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The SF-12 generic quality o f life questionnaire
Excellent Very good Good Fair Poor
1. In general, would you say your health is □ □ □ □ □
The following questions are about activities you might do during a typical day. Does your health now limit you in these 
activities? If so, how much?
Limited a 
lot
Limited a 
little
Not limited 
at all
2. Moderate activities, as moving a table, pushing 
a vacuum cleaner, bowling, or playing golf?
□ □ □
3. Climbing several flights of stairs □ □ □
During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a 
result of your physical health?
Yes No
4. Accomplished less than you would like □ □
5. Were limited in the kind o f work or other 
activities
□ □
During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a 
result of any emotional problem (such as feeling depressed or anxious)?
Yes No
6. Accomplished less than you would like □ □
7. Didn't do work or other activities as carefully as 
usual
□ □
Not at all A little bit Moderate Quite a bit Extreme
8. During the past 4 weeks, how much did pain 
interfere with your normal work (including both 
work outside the home and housework?
□ □ □ □ □
These questions are about how you feel and how things have been with you during the past 4 weeks. For each question, 
please give the one answer that comes closest to the way you have been feeling. How much ofthe time during the past 4 
weeks:
All o fthe  
time
Most of 
the time
A good bit 
o fthe  time
Some of 
the time
A little of 
the time
None of 
the time
9. Have you felt calm and peaceful? □ □ □ □ □ □
10. Did you have a lot o f energy? □ □ □ □ □ □
11. Have you felt downhearted and low? □ □ □ □ □ □
All o fthe  
time
Most of 
the time
Some of 
the time
A little of 
the time
None of 
the time
12. Has your physical health or emotional problems 
interfered with your social activities (visiting 
friends, relatives, etc.)?
□ □ □ □ □
© Copyright 1994 The Health Institute New England Medical Centre. All Rights reserved.
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Chapter 3  Aetiology o f benign prostatic 
hyperplasia
Introduction
Benign prostatic hyperplasia (BPH) is one of the most common conditions 
affecting elderly men. The prevalence of histological BPH increases with age, 
starting around the age of thirty and rising steadily to almost 90% in the ninth 
decade of life [Berry et al., 1984]. Much effort has been put in studying the 
molecular and endocrine processes that may be involved in the aetiology of BPH 
and many epidemiological studies investigated putative risk factors. Unfortunately, 
these efforts have not yet resulted in any prospect for prevention. This review 
summarises the risk factors that have been suggested for the development of BPH. 
A brief description of the growth regulation of the prostate gland is given as a basis 
for the review.
Growth regulation
Hormonalfactors
Advanced age and the presence of functioning testes are the two best-established 
factors required for the development of BPH. The role of the testes is related to 
their ability to secrete androgens and, to a lesser extent, estrogens. The prostate is 
highly androgen dependent for its growth and its structural and functional integrity 
[Lee et al., 1995]. Although BPH has once been reported in a phenotypic male 
with an XX karyotype and castrate levels of testosterone [Marinello et al., 1979], 
the disease does not normally occur in males castrated before puberty or in males 
with disorders of androgen production or action [Wilson, 1996]. Furthermore, 
bilateral orchiectomy results in atrophy of the prostate. The age related risk of BPH 
is attributed to changes in endocrine environment and to an increasing imbalance 
between stimulatory and inhibitory growth factors [Griffiths et al., 1998].
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The principal androgen, testosterone, is mainly produced in the testes. Mediated by 
luteinizing hormone (LH), the hypothalamus-pituitary-testis axis strictly regulates 
blood levels of testosterone. Prolonged stimulation of the LH releasing hormone 
receptor with LHRH analogues desensitises the receptor, thereby inhibiting LH 
secretion and reducing the level of testosterone. This mechanism has been evaluated 
for its therapeutic value with conflicting results and is seldom used in urological 
practice [Peters and Walsh, 1987; Comaru-Schally et al., 1998]. Homozygosity for 
a common genetic variant of LH is associated with elevated levels of testosterone 
and possibly with early onset prostate cancer [Pettersson et al., 1998]. The 
frequency of occurrence of this variant ranges from 42% in Finnish Lapps to 7% in 
US Hispanics. The importance of this genetic polymorphism in the aetiology of 
BPH awaits further clarification.
Some testosterone also originates from the adrenal gland under control of adreno- 
corticotrophic hormone (ACTH) and possibly by prolactin [Kadar et al., 1988]. 
Some evidence from an animal model suggests that prolactin acts synergistically 
with testosterone in causing prostatic enlargement [Wennbo et al., 1997].
Testosterone is metabolised to dihydrotestosterone (DHT) by 5a-reductase (5aR), 
located on the nuclear membrane of prostatic cells. A rare autosomal-recessive form 
of male pseudohermaphroditism is caused by mutations in the 5aR gene, despite 
normal levels of testosterone [Wilson et al., 1974; Imperato-McGinley et al., 1979]. 
Two isoenzymes of 5aR have been described, with type 2 being mainly involved in 
prostate development. Regression of prostate size and improvement of urodynamic 
parameters in men with BPH can be produced by pharmacological inhibition of 
5aR-2 with finasteride. A recent study showed that finasteride improves 
urodynamic measures of obstruction in men with BPE and LUTS, with continued 
improvement during the second 12 months of therapy [Schäfer et al., 1999]. 
Nevertheless, the effect appears to be of limited clinical value [Boyle et al., 1996].
Intranuclearly, D H T binds to the androgen receptor, and the complex associates 
with the genome. This interaction leads to modulation or initiation of transcription 
of genes concerned with cellular growth processes. A polymorphism in the number 
of CAG repeats in the androgen receptor gene has been associated with larger 
adenomas [Mitsumori et al., 1998] and increased risk of surgery for BPH 
[Giovannucci et al., 1999]. In another study, no clear association was seen between
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this polymorphism and BPH [Bousema et al., 2000]. In addition, the latter study 
found no relation with a vitamin D receptor polymorphism, although this receptor 
is sometimes said to interact with the same response elements on the genome as the 
androgen receptor complex does.
Next to testosterone and DHT, estradiol is the third steroid hormone involved in 
the pathogenesis of BPH, although its role is less clear [Farnsworth, 1999]. 
Estradiol, which is mainly produced by aromatase activity from adipose tissue, 
modulates the action of androgens by altering the sensitivity of the prostate to 
androgens. A small increase in estradiol concentrations results in an increase in the 
number of androgen receptors and prostate size. Alternatively, a large increase in 
estradiol concentration can have the opposite effect. Presumably, some of the effects 
on androgen sensitivity are imprinted in utero by maternal estradiol levels and are 
sustained throughout adult life.
Cell proliferation and apoptosis
Prostate growth is under the immediate control of specific growth stimulating and 
inhibiting factors, such as transforming growth factor, basic fibroblast growth 
factor, keratinocyte growth factor, and epidermal growth factor. In addition, 
growth factors appear to be implicated in bladder hypertrophy secondary to BOO 
[Lawson, 1997]. Any disturbance of the fine balance in growth factors may thus 
lead to the occurrence of BPH and LUTS.
W ithin the prostate, there is a clear regional variation in the proportion of epithelial 
tissue to the surrounding stromal tissue. The stroma surrounding the ducts 
manifests heterogeneity as far as the distribution of smooth muscles is concerned. It 
is now well accepted that an interaction between stromal tissue and epithelial tissue 
plays a role in the development of the prostate. Androgens mediate their effects 
primarily on the stroma and thereby produce inductive signals that influence 
epithelial growth and differentiation. It is furthermore hypothesised that stroma can 
re-attain embryonic properties, which might induce the epithelium to renew 
growth [Isaacs and Coffey, 1989].
Next to enhanced cell proliferation, the benign enlargement of the prostate 
observed at advanced age, may also be due to the fact that cells loose their ability to
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die. This programmed cell death or apoptosis occurs by DNA fragmentation, which 
results from activation of Ca++ / Mg++ dependent endonuclease. Androgen 
dependent cells may be prevented from apoptosis by the presence of 
(dihydro)testosterone. Manipulation of the chemical reactions leading to 
programmed cell death is likely to influence the aetiology of BPH.
Adrenoceptors
Adrenergic and cholinergic receptors are both present in prostatic smooth muscles, 
surgical capsule, and bladder neck. The adrenergic nerves determine the smooth 
muscle tone inside the prostate by stimulating post-synaptic a1-receptors. Prostatic 
^-adrenergic receptors have been subtyped into a1A-, a 1B-, and a1D-receptors, with 
a 1A-receptors being mainly responsible for the contractile properties of human 
prostatic adenomas [Forray et al., 1994]. Other subtypes, however, may also be 
important. Randomised controlled trials showed that selective a 1-adrenoceptor 
antagonists reduce symptoms of BPH and improve urinary flow rates [e.g. Lepor et 
al., 1996], demonstrating the importance of a dynamic component of BPH.
Risk factors
The increased understanding of the regulation of prostatic growth led to the idea 
that environmental and constitutional factors that alter the concentration of steroid 
hormones or growth factors as well as mechanisms that interfere with stromal- 
epithelial interaction or programmed cell death, may also contribute to the 
aetiology of BPH [Oishi et al., 1998]. Table 3.1 gives a summary of the most 
important studies on risk factors for BPH.
Comparable to the study of the prevalence and incidence of BPH, epidemiological 
studies into these environmental influences have been hampered by the lack of a 
clear definition of the disease. Only about 50% of all microscopically identifiable 
BPH lesions ever give rise to a macroscopically enlarged prostate [Oesterling, 
1996]. An enlarged prostate may obstruct the urethra leading to LUTS, although 
many of the more bothersome symptoms are caused by the resulting bladder 
hypertrophy. Moreover, an enlarged prostate not always causes LUTS, and LUTS is
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Table 3.1_______ Characteristics o f selected studies on risk factors for benign prostatic hyperplasia
First author Study base Study type Study size Years of enrolment Disease definition Risk factors assessed
Cetinkaya [1998] patients with hepatic cirrhosis and 
healthy volunteers
case-control 80 LUTS and prostate 
volume
hepatic cirrhosis
Danieli [1993a,1993b] patients scheduled for TURP and 
internal medicine office controls
case-control 432 1984-1988 prostatectomy smoking, obesity
Morrison [1992] Rhode-lsland hospitals case-control 2,913 1985-1987 prostatectomy smoking, alcohol, marital 
status, religion, coffee
Sanda [1994] family of patients and their spouses 
in Johns Hopkins
case-control 165 1985-1992 prostatectomy family history
Kupeli [1997] patients scheduled for TURP case-series 68 clinical BPH smoking
Matzkin [1996] patients with LUTS case-series 195 prostate volume smoking
Pressler [1997] untreated patients with LUTS case-series 326 LUTS hypertension
Sanda [1997] finasteride trial case-series 414 prostate volume family history
Koskimaki [1998] community dwelling Finnish men cross-sectional 2,128 1994 LUTS smoking
0  Table 3.1_______ Characteristics o f selected studies on risk factors for benign prostatic hyperplasia (continued)
First author Study base Study type Study size Years of enrolment Disease definition Risk factors assessed
Lee [1997] Yochon County, Korea cross-sectional 514 1995 LUTS smoking, obesity, alcohol
Roberts [1994; 1995] Olmsted County cross-sectional 2,115 1989-1991 clinical BPH smoking, family
Roberts [1997] Shimamaki-mura, Japan cross-sectional 286 1990-1992 clinical BPH smoking
Partin [1994] W W  II Military Twin Cohort cross-sectional / 
twin study
482 1985 benign prostatic 
disease
family history
Giovannucci [1994], 
Platz [1998]
Health Professionals Follow- 
up Study
follow-up 25,892 1986 with follow-up 
until 1992
LUTS and 
prostatectomy
obesity, physical activity
Glynn [1985] VA Normative Aging Study follow-up 1,747 1961-1970 with follow- 
up until 1982
clinical BPH and 
prostatectomy
smoking, obesity, alcohol, 
hypertension, religion, socio­
economic status
Seitter [1992] Rancho Bernardo follow-up 895 1972-1974 with follow- 
up until 1987
prostatectomy smoking, obesity
Sidney [1991] Kaiser Permanente Medical 
Care Program
follow-up 16,219* 1971-1972 with follow- 
up until 1987
prostatectomy smoking, obesity, urine pH, 
alcohol, kidney radiography, 
vasectomy, tuberculosis
*  8,292 for multivariate analyses
not always caused by BOO; for instance, detrusor instability and detrusor 
underactivity may yield similar complaints. When interpreting the results of 
epidemiological studies on BPH, one must bear in mind that these various disease 
definitions, i.e., histological BPH, BPE, BOO and LUTS may well have a different
Smoking
Cigarette smoking is the most extensively studied putative risk factor for BPH. 
Although conclusive evidence is still lacking, both androgen and estrogen levels 
seem to increase as an effect of smoking cigarettes due to their nicotine content. 
Thus, if smoking has any biological effect on the aetiology of BPH, it is probably 
inductive. Most epidemiological studies of smoking associated BPH, however, 
failed to show any relation or found an inverse relation instead (figure 3.1).
Koskimaki [1998]
Küpeli [1997]
Lee [1997]
Roberts [1997]
Roberts [1994]
Daniell [1993a]
Morrison [1992]
Seitter [1992]
Sydney [1991]
Glynn [1985]
0.1 0.5 1 2 10
Risk ratio and 95% confidence interval of current smokers versus non-smokers
Figure 3.1 Association between smoking and BPH. Because o f differences in design, 
care should be taken when comparing the results o f these studies.
j I I
Symptoms
Surgery
t------------------ 1-----------------r
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Glynn and colleagues [1985] reported data of over 1,700 men from the 
longitudinal VA Normative Ageing Study in Boston, Massachusetts. They found a 
moderate protection for undergoing prostatectomy by smoking one pack of 
cigarettes per day compared to not smoking (Risk Ratio (RR) = 0.43; 95% 
Confidence Interval (CI): 0.17 - 1.12). The probability of a clinical diagnosis, i.e., 
diffuse enlargement on manual rectal palpation, was comparable between both 
groups (RR = 0.92; 95% CI: 0.71 - 1.19).
Sidney and coworkers [1991] followed a cohort of over 16,000 members of the 
Kaiser Permanente Medical Care Program in California, although they had to 
exclude almost 50% of the subjects in multivariate analysis because of missing 
values. Smoking at initial evaluation carried a 25% (95% CI limits -41% ; -6%) 
decrease in risk for subsequent prostatectomy, while former smokers had a 16% 
decreased risk (95% CI limits: -32% ; +3%). It seems implausible that an inverse 
association between smoking and BPH is hormonally mediated. An alternative 
explanation might be that smokers are less likely candidates for surgery because of 
smoking associated comorbidity, or that they are less likely to survive to the age of
Seitter and Barrett-Connor [1992] found no overall association between smoking 
and surgically treated BPH in a twelve-year follow-up study of 895 white male 
residents from Rancho Bernardo, California. Some evidence of effect modification 
by age and Body Mass Index (BMI) was present, however, suggesting an increased 
risk due to smoking only for moderate to severe obese and older men. It should be 
noted that the authors restricted the analyses to subjects who survived the first ten 
years of follow-up. Consequently, they might have introduced differential loss-to- 
follow-up, if smokers die prematurely because of smoking related diseases.
In a case-control study performed among 2,913 Rhode Island inhabitants, 
Morrison [1992] found a weak negative association between smoking and 
prostatectomy. Smoking status two years prior to the interview was used as 
exposure of interest. Because of this definition of smoking status, the authors 
assured that exposure information represented the situation before prostatectomy. 
Nevertheless, it remains difficult to make any inference regarding the relevant time 
at which to measure smoking status as long as a causal pathway of smoking in the 
aetiology of BPH is not clear.
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Daniell [1993a] assessed the association between smoking status and frequency of 
prostatectomy in a case-control study. Cases were 432 patients who underwent 
TURP in Mercy Medical Center, California. Two separate control groups served as 
approximations of person time at risk: colon cancer patients and patients visiting 
the office practice of general internal medicine, both from the same hospital. 
Smokers are likely to be overrepresented in both control groups, which would make 
the RR estimations invalid. Furthermore, the applied definition of smoking status 
did not distinguish between former and current smokers, even though other studies 
have shown former smokers to be more similar to never smokers with respect to the 
probability of undergoing prostatectomy [Morrison, 1992]. W ith these limitations 
in mind, it is difficult to compare the results of this study (a small reduction in risk 
among current smokers) with the results found in other studies.
Roberts and colleagues [1994], cross-sectionally studying 2,115 men from Olmsted 
County, Minnesota, did find an increase in moderate to severe urological 
symptoms among heavy smokers compared to never smokers. Light smokers, 
however, appeared to have a decreased risk. According to the authors, this biphasic 
relation between cigarette smoking and BPH may be explained by the dual effect 
which nicotine has at post-synaptic parasympathetic receptors in and around the 
bladder, acting as an agonist at low doses and as an antagonist at high doses. Thus, 
low doses of nicotine may improve bladder function, while high doses have the 
opposite effect. All smokers combined were less likely to have peak flow rates less 
than 15 ml/s and to have prostate volumes greater than 40 ml. Its cross-sectional 
study design and the small percentage of current smokers (16%) hampered the 
study. The small number of smokers may imply an unrepresentative study 
population or indicate misclassification of exposure leading to underestimated effect 
measures.
Roberts and colleagues [1997] also conducted a similar study among 286 Japanese 
men, with comparable results as those found among Olmsted County men for all 
smokers combined and for ex-smokers. In Japan, however, light smokers were at 
increased risk to have moderate to severe symptoms and to have an enlarged 
prostate. Comparable Olmsted County men were less likely to have moderate to 
severe symptoms and to have an enlarged prostate, compared to never smokers.
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Lee and colleagues [1997] studied 514 Korean men, selected by random cluster 
sampling from a general population of over 60,000 residents of Yonchon County. 
Subjects with conditions that might interfere with normal voiding as well as those 
who previously underwent prostatic surgery were excluded. This exploratory study 
related symptom scores assessed by the Korean version of the IPSS to several socio­
demographic, physical and laboratory findings. Heavy smokers (> 1 pack per day) 
were at increased risk of having moderate to severe symptoms, although the RR of 
1.56 compared to non-smokers was not statistically significant at a 5% level in 
multivariate analyses (95% CI: 0.69 - 2.51). Possibly, the group of patients that was 
excluded based on previous prostatic treatment contains a relative large number of 
smokers, resulting in an underestimation of the effect of smoking on BPH.
Using a cross-sectional study design, Küpeli and others [1997] observed a weak 
inverse relation between smoking and prostate size, symptom score and urinary 
flow rate, among 68 men with obstructive uropathy scheduled for TURP. In this 
selected group of patients, smokers on average also had higher serum levels of 
estradiol, but free testosterone levels were similar for smokers and non-smokers.
Koskimaki and colleagues [1998] studied the association between smoking and 
LUTS in community dwelling Finnish men. Symptoms were assessed by a 
modified Danish Prostate Symptom Score, combining the presence of symptoms 
with the associated bother. Current and past smoking habits were gathered from 
self-administered mailed questionnaires. In this study, current smokers showed an 
increased risk of having LUTS compared to never smokers (RR = 1.39; 95% CI:
1.02 - 1.93), after adjusting for a wide range of covariates. The results for former 
smokers were similar to those for current smokers, possibly indicating that direct 
effects of smoking on the dynamic component of LUTS are not involved. After 
cessation of smoking, however, a gradual decrease in symptoms was observed, 
suggesting for one that the process is reversible, but for another that recovery is a 
long-term process.
In another cross-sectional study, Matzkin and coworkers [1996] observed no 
difference in prostate volume between 195 current, ex- and never smokers with 
LUTS. Self-reported smoking history was combined with results from transurethral 
ultrasonography of the prostate. The authors suggested that previously observed 
protective effects of cigarette smoking may be mediated through factors other than
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gland size, possibly the effect of smoke components on a-tonicity of the prostate 
and bladder neck. This effect would minimise the dynamic component of 
obstruction.
In conclusion, epidemiological studies reveal little evidence of a hormonally 
mediated response of smoking to a biologically expected increase in risk of 
(surgically treated) BPH, although some evidence suggests an elevated risk of 
experiencing bothersome symptoms. Other studies even found an inverse 
association. Any effect of smoking related to BPH, however, is likely to be weak, if 
existing at all. Therefore, understanding the influence of smoking might add to our 
knowledge of disease mechanisms rather than having practical implications.
Obesity
Obese men produce more estradiol than non-obese men, through transformation of 
adrenal androstenedione in adipose tissue. Underweight, on the other hand, has 
been related with increased testosterone levels [Eldrup et al., 1987]. These 
mechanisms make an increased risk for both obese and lean people biologically 
plausible.
Four longitudinal studies looked at obesity as a potential risk indicator for BPH 
(figure 3.2). Both Glynn et al. [1985] and Sidney et al. [1991] observed slightly 
reduced risks for more obese people in multivariate analysis. Seitter and Barrett- 
Connor [1992] did not observe substantial differences between strata of obesity. 
Prostatectomy was used as objective outcome measure in these studies, although 
Glynn and colleagues also assessed differences in occurrence of clinical diagnosis. 
Notably, they did not find an effect when using prostatectomy as outcome, but 
there was a small negative effect when considering clinical diagnosis as definition of 
BPH. The authors suggested the inherent difficulty in assessing prostate size in 
obese men as an explanation for this difference.
Giovannucci and others [1994] followed a cohort of male US residents between 
1986 and 1992 as a part of the Health Professionals Follow-up Study. Over 25,000 
subjects aged 40 years and over, without prior diagnosis of BPH or cancer, returned 
a postal questionnaire with information on height, weight, and waist- 
circumference.
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Giovannucci [1994] II
Daniell [1993b] III 
IV
Seitter [1992] I 
II
Sydney [1991] III 
IV
Glynn [1985] +5 kg/m2
0.1 0.5 1 2 10
Risk ratio and 95% confidence interval of succesive categories of obesity (II - IV) versus leanest
category (I)
Figure 3.2 Association between obesity and prostatic surgery. Because o f differences 
in design, care should be taken when comparing the results o f these 
studies.
After six years, a second questionnaire assessed the presence of LUTS and BPH- 
related surgery since baseline. The results of this study revealed that waist- 
circumference (adjusted for height) is linearly related to both symptoms and 
surgery. Multivariate adjusted RR for surgery of the most obese group versus the 
leanest group was 1.47 (95% CI: 1.06 - 2.04). The RR for the presence of 
symptoms was 1.43 (95% CI: 1.18 - 1.74). There was no evidence of a U-shaped 
relation. BMI was not independently related to BPH in this study.
Daniell [1993b] compared 379 patients, all of whom underwent TURP, with 
respect to the weight of the resected tissue. He concluded that obesity quantified by 
deviation from a standardised weight for height distribution is a risk factor for 
prostatic enlargement. This relation was most apparent in men aged 60 years and 
older. Comparing the standardised weight for height distribution of the TURP 
patients to that of randomly selected internal medicine office controls with a similar
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age distribution, showed that obesity was unrelated to uropathy requiring surgery. 
Some limitations of this study have been described in the paragraph on smoking.
Lee and colleagues [1997] assessed abdominal obesity, quantified by the waist-to- 
hip ratio, in their cross-sectional study among 514 Korean men. A biphasic relation 
with LUTS was observed, with highest prevalence of moderate or severe symptoms 
for lean and obese men, compared to men of average weight. The differences 
persisted in multivariate analyses, controlling for age, smoking habits, alcohol 
consumption and serum HDL level.
Soygür and coworkers [1996] studied 68 men with BOO and documented larger 
adenomas in men who were at least 40% over recommended weight. The authors 
did not observe an increase in symptoms and concluded that obesity might be a risk 
factor for prostatic enlargement, but not for obstruction.
In conclusion, obesity may be associated with prostatic enlargement, but firm 
evidence for a relation of obesity with either symptoms or obstruction requiring 
surgery is lacking. BMI is often used as measure for obesity. Due to an age-related 
decrease in stature and change in bone density, however, BMI is an increasingly 
invalid measure of obesity with advanced age. Therefore, any finding on BMI is 
questionable in the elderly. Further studies on the relation between obesity and 
BPH should pay more attention to other measures of obesity than BMI. The waist- 
to-hip ratio to quantify fat-distribution or waist-circumference to estimate 
abdominal fat-mass, offer attractive alternatives [Lean et al., 1996].
Alcohol consumption and liver cirrhosis
Alcohol consumption decreases testosterone production, and increases testosterone 
clearance. Therefore, alcohol consumption may reduce the risk of developing BPH. 
Indeed, Morrison [1992] reported a multivariate adjusted RR of 0.49 (95% CI: 
0.32 - 0.77) for drinking three glasses of alcohol per day compared to less than one 
glass per day. The apparent protection by alcohol was strongest for consumption of 
beer (RR = 0.30; 95% CI: 0.14 - 0.63). Sidney and associates [1991] also found a 
lower risk for subjects who drank three or more glasses of alcohol per day compared 
to non-drinkers (age-adjusted RR = 0.75; 95% CI: 0.60 - 0.94). As both studies 
used BPH surgery as outcome, the association could be due in part to the poorer
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surgical risk of heavier drinkers. Lee and colleagues [1997] also reported a trend 
towards lower risk of symptomatic BPH with increasing amount of daily intake of 
beer. The results found by Glynn and coworkers [1985] for both prostatectomy 
and clinical diagnosis of BPH related to alcohol intake are close to unity.
Some authors suggested that hepatic cirrhosis also reduces one’s risk of BPH. The 
disturbed metabolic activity of the cirrhotic liver may lower androgen levels. 
Cetinkaya and colleagues [1998] compared hormonal status, prostate volume, and 
symptom scores of 60 patients with hepatic cirrhosis with that of 20 healthy 
volunteers. Serum testosterone, gland size and symptom scores were all significantly 
decreased in the case group, while serum estradiol level was comparable in both 
groups. Four previously published autopsy studies confirmed a somewhat lower 
prevalence of histological BPH among men with hepatic cirrhosis compared to 
those without cirrhosis [Bennett et al., 1950; Stumpf and Wilens, 1953; Robson, 
1966; Frea et al., 1987]. One study found a positive crude association [Wu, 1942]. 
Most cases of cirrhosis were alcohol related, which makes the separation of the 
effects of alcohol and cirrhosis virtually impossible. Moreover, the reported effects 
of cirrhosis on BPH were weak, with RRs in the range of 0.8 to 0.9.
Family History
Following the research on prostate cancer, studies have been conducted to show 
whether high penetrance genetic mechanisms and/or major genes exist in BPH 
(figure 3.3). Roberts and others [1995] described data from the Olmsted County 
Study, regarding the association between family history of BPH and moderate to 
severe LUTS in the month before the interview. Men with a first degree male 
relative with prostatic enlargement had a 30 percent increase in risk compared to 
men without such family members, after controlling for age and worry (95% CI: 
10% - 70%). The increase in risk was greatest among men with relatives diagnosed 
before the age of 60 (RR = 2.5; 95% CI: 1.5 - 4.3). Men with a positive family 
history were also 1.3 times more likely to have an impaired peak urinary flow rate 
(<15 ml/s). The information from a sample of the self-administered questionnaires 
was then compared to the corresponding medical records in order to assess the 
magnitude of misclassification of exposure. It was impossible to validate eight 
percent of the affirmative answers, whereas 30 percent of the alleged negative
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answers was incorrect. Surprisingly, the information of men with moderate to 
severe symptoms seemed more reliable than that of men with no or only mild 
symptoms. Thus, some recall bias may have diluted the results.
Sanda [1997] 
prostatic volume
Partin [1994] 
benign prostatic disease
Sanda [1994] 
prostatic surgery
Roberts [1995] 
symptoms
0.1 0.5 1 2 10
Risk ratio and 95% confidence interval versus no familiy history
Figure 3.3 Association between family history and BPH. Because o f differences in 
design, care should be taken when comparing the results o f these studies.
Sanda and colleagues [1994] from Baltimore tried to answer the question whether 
having a first-degree male relative who underwent surgery for a greatly enlarged 
prostate at an early age increases the risk of having to undergo prostatectomy. The 
response with respect to prostatectomy among family members was not validated. 
Misclassification of disease can therefore not be ruled out, and is likely to be 
differential. The 340% increase in risk for men with an affected family member 
that was found in this study should thus be interpreted with some caution. A 
segregation analysis based on this dataset, suggested Mendelian dominant 
inheritance of a gene associated with early age at onset of BPH.
In another study, among patients enrolled in a 5a-reductase inhibitor trial, Sanda 
and coworkers [1997] compared various clinical parameters according to whether
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or not the patient had two or more “BPH” affected family members. The authors 
did not elaborate on the meaning of “BPH” affected, although they did state that it 
was based on proband recall, allowing the possibility of recall bias. The main results 
from this study were a larger mean prostate size and higher serum PSA levels among 
patients with familial BPH, while differences in other parameters (symptom score, 
maximum urinary flow rate, age, and serum (dihydro)testosterone) were small.
Partin and associates [1994] looked for differences in concordance rates between 
monozygotic and dizygotic twin pairs, using the World War II Military Twin 
Cohort. Here, concordance means that both twins responded affirmatively to a 
postal questionnaire with reference to surgery or hospitalisation for prostatic 
disease. The response quoted by the participants as reason for medical treatment 
was as vague as “prostate” in over 50% of the reported cases, while less than two 
percent specifically mentioned BPH. It is therefore likely that among cases there is a 
considerable proportion of men with prostate cancer, which most likely has a 
different aetiology than BPH. It should also be acknowledged that twin studies 
assume environmental factors to be similar between monozygotic and dizygotic 
twins. Nevertheless, the 3.3 fold increased risk for monozygotic twins may reflect a 
difference in genetic predisposition to the disease.
Studies trying to demonstrate a genetic basis for BPH face several difficulties. The 
most prominent drawback lies in the fact that direct exposure measurement, that is 
genetic predisposition, is impossible in the absence of a specific gene to study. 
Therefore, investigators have few more options than to use proxy variables. The use 
of such variables will inevitably introduce misclassification of exposure. The single 
most often used proxy is (self-reported) family history of disease, but this proxy 
may not capture all those with disease. The same problem that acts upon disease 
definition of BPH, now also pertains to the definition of exposure. As mentioned 
earlier, there is a need for well-defined disease and exposure definitions and future 
studies must pay major attention to obtaining reliable information for both.
Hypertension
A study from the 1960s reported elevated blood pressure for patients admitted to 
surgery for prostatic disease compared to patients admitted for non-genitourinary 
elective surgery, suggesting blood pressure to influence the aetiology of BPH
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[Bourke and Griffin, 1966]. The authors of this study may well have reversed the 
actual time sequence, however, in that hypertension is a sequel rather than a cause 
of prostatic obstruction. Another possible explanation is that a dynamic obstruction 
of the prostate and (diastolic) hypertension resulting from an increased vascular 
wall stress, have a common a-receptor related causal mechanism. Glynn and 
coworkers [1985] included systolic blood pressure in their analysis and found no 
association with either clinical diagnosis or prostatectomy. Pressler and others 
[1997] correlated the incidence of hypertension (systolic pressure > 140 mmHg or 
diastolic pressure > 90 mmHg) with the IPSS in 326 men with untreated BPH. 
Among men with mild (0-7), moderate (8-19) and severe (> 20) symptoms the 
prevalence of hypertension was found to be 15%, 18% and 31%, respectively. 
These data do suggest a potential common aetiology, but further research is needed 
to elucidate the relationship between these two common conditions by follow-up 
studies.
The metabolic syndrome
A new hypothesis on the aetiology of BPH involves the so-called metabolic 
syndrome. Denoted Syndrome X by Reaven in 1988, this condition is characterised 
by a defective insulin-mediated glucose uptake and a compensatory hyper- 
insulinaemia. It may predispose to the development of a large group of common 
metabolic disorders, including non-insulin-dependent diabetes mellitus (NIDDM), 
obesity, hypertension, hyperlipidaemia and atherosclerosis [DeFronzo and 
Ferrannini, 1991]. Possibly, patients with BPH have the same primary metabolic 
disorder. Furthermore, induced hyperinsulinaemia has been shown to increase 
sympathetic activity [Berne, 1989]. Consequently, the metabolic syndrome may in 
part also be responsible for a-receptor mediated changes in urethral obstruction. 
Moreover, as a-blocker medication is known to increase insulin sensitivity and 
decrease insulin levels [Shieh et al., 1992], this therapy, in addition to having a 
beneficial effect on urethral obstruction, may also slow down the development of 
histological BPH.
A study by Hammarsten and coworkers [1998] showed that patients with LUTS 
having NIDDM , treated hypertension, obesity or low HDL levels, had larger 
prostate volumes than patients with LUTS without such manifestations of the
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metabolic syndrome. A second study from the same department showed a high 
prevalence of the metabolic syndrome among patients with LUTS having a fast 
annual prostate growth rate compared to those having a slow annual growth rate 
[Hammarsten and Hogstedt, 1999]. The results of these two studies, albeit 
speculative, may link several suggested causative factors in the development of 
BPH, including hypertension and obesity, to a common entity. Future studies are 
necessary to confirm the results from Hammarsten and associates. It must be 
suspected, however, that the inherent difficulties to measure the ill-defined 
metabolic syndrome and to define BPH, prostatic enlargement, BOO, and LUTS, 
pose enormous problems to identify any clear relation.
Racial differences
Guess [1992] presented a detailed review of racial differences in the prevalence and 
incidence of BPH. The life-long probability for Western men to undergo 
prostatectomy for BPH is approximately 25-30%. African-American men have 
identical overall risk of surgically treated BPH. This figure is much lower in many 
Asian countries. Next to differences in prostatic growth and regulation mechanisms 
between races, different health care facilities and acceptance of ageing are probably 
responsible for the observed differences. Recently, Platz and coworkers [2000] 
published a study of racial differences in the occurrence of BPH based on the 
Health Professionals Follow-up Study. They concluded that racial and ethnic 
variation is evident in the incidence of BPH surgery and symptom severity. In this 
study, no increased risk for BPH was found for black men compared with white 
men (RR = 0.85; 95% CI: 0.55 - 1.31). Asian men were less likely to have 
undergone BPH surgery (RR 0.41; 95% CI: 0.21 - 0.82), although the RR for 
symptoms was similar to that of white men.
Miscellaneous
In the pursuit of risk factors for BPH, several potential indicators have been 
examined in exploratory studies. For most of these relations, a convincing biological 
mechanism is lacking and most factors have only been analysed once. Hence, the 
results must be interpreted with caution. Morrison [1992] found elevated risks for 
Jewish men, for men who never married and for coffee drinking. Glynn and others
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[1985] also found an increased risk among Jews. In addition, they identified lower 
socio-economic status as a possible risk indicator. Sidney [1987], once more based 
on the Kaiser Permanente data set, reported a 1.2 fold increased risk of having a 
hospital diagnosis of BPH (95% CI: 0.7 - 1.8) for men who had undergone 
vasectomy. In an update of this study, however, the RR levelled off at 0.97 (95% 
CI: 0.8 - 1.3). Until now, there is no consistent evidence of an association of sexual 
activity in relation with BPH [Guess, 1992]. Once again based on the Health 
Professionals Follow-up Study, Platz and coworkers [1998] related increased 
physical activity to a lower frequency of LUTS. The multivariate adjusted RR 
comparing the extreme quintiles of physical activity was 0.75 (95% CI: 0.64 - 
0.87). The result for prostatic surgery was almost identical. The analyses were not 
corrected for obesity, although both factors are clearly interrelated. Thus, it is not 
evident that physical activity has an independent effect on BPH, apart from its 
effect on overweight. Sidney and others [1991] found that urine pH > 5 and a 
history of tuberculosis and kidney radiography raise the probability of having to 
undergo prostatectomy.
Perspectives
Much effort has been put into the search for aetiological factors for BPH, yet no 
firm evidence for the presence of any of the examined factors has come forth. 
Consequently, a lot of work still has to be done in this area. Epidemiological studies 
should focus on biologically plausible risk factors based on the increasing body of 
knowledge concerning the molecular and endocrine pathways regulating prostatic 
growth. Furthermore, several difficulties in the design and analysis stage of such 
studies must be considered.
Firstly, the likely differences in aetiology of various disease definitions of BPH must 
be acknowledged in all studies. For instance, the possible smaller risk of 
prostatectomy related to smoking cannot be distinguished from the higher 
cardiovascular and pulmonary co-morbidity, making smokers less likely candidates 
for surgery. Consequently, prostatectomy should not be used to study the effect of 
smoking on BPH. Likewise, hypertension may be associated with the dynamic 
component of BOO, but not with the presence of histological prostatic lesions.
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Secondly, the exposure of interest in each study must be clearly defined. When 
studying family history the same problem with disease definition holds for the 
definition of exposure. Furthermore, relevant levels of exposure must be compared. 
For instance, if a U-shaped relation is hypothesised to be present (both lean and 
obese men may be at increased risk for BPH) the extreme categories should not be 
compared directly, but the middle group should be used as a reference instead.
Thirdly, it remains difficult to make any inference regarding the relevant time at 
which to measure exposure status as long as a causal pathway for putative risk 
factors in the aetiology of BPH is not clear. This consideration holds for all time 
varying, putative risk factors (e.g., smoking, alcohol consumption and obesity). 
Most of the described follow-up studies use a single exposure measurement at 
baseline. Others measure exposure at consecutive medical check-ups and use most 
recent exposure. Now that the methodology of repeated measurement analysis in 
longitudinal studies has received more attention, time varying exposure assessment 
should be used more often.
Fourthly, causal mechanisms are ideally investigated in follow-up studies among 
subjects at risk of getting the disease. For example, if one wants to study the effect 
of hypertension on BPH, it is necessary to use a follow-up design to assure a correct 
temporal sequence of cause and effect. Alternatively, a properly designed case- 
control study can be conducted, with controls representing person time drawn from 
the population of people at risk. Self-reported history of exposure, however, is 
subject to differential misclassification.
Fifthly, a careful consideration of multivariate analyses is required. Correction for 
confounding only makes sense if the potential confounder is a well-established risk 
factor for the disease. As such factors are not known for BPH, apart from age and 
the presence of circulating androgens, correction for a wide range of covariates is 
not mechanism-based and may in fact adversely influence the power of the analyses. 
In addition, correction for age is not always called for. Age must be considered a 
proxy variable for changes in the endocrine environment and in the balance 
between inhibiting and stimulating growth factors. If these effects are controlled 
for, an existing association with BPH may be masked. At the other hand, correcting 
for changing smoking behaviour or alcohol consumption with age or with ageing 
cohorts, is without any doubt sensible.
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Due to the limitations facing aetiological research for BPH, all plans to study risk 
factors should be considered critically. For all such studies, it must be assured that 
the expected outcome is significant enough to justify the efforts and costs.
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Part 2 
Reproducibility

Chapter 4  Variability o f maximum urinary flow 
rate
Introduction
In the evaluation of diagnostic tests, issues of validity and reproducibility are 
usually distinguished. Discussion continues regarding the preferred sequence of 
research. Some hold that it is best to begin with a study of the test’s reproducibility, 
since a poorly reproducible test cannot possibly be useful in practice. Others claim 
that proper test evaluation must begin with validity analysis, as there is no interest 
in reproducibility if the test correlates well with the gold standard. This thesis 
addresses the principles of diagnostic research, focussing on ill-defined diseases such 
as LUTS. As ill-defined diseases are characterised by the absence of a gold standard, 
validity research is troublesome in these instances. Study of a test’s reproducibility 
does not require a gold standard. Therefore, we address issues of reproducibility 
before issues of validity.
Reproducibility is the degree to which repeated measurements of the same signal 
fluctuate. The variability of repeated measurements must be compared to a relevant 
frame of reference. For instance, the variation in repeated measures of a diagnostic 
test result must be small relative to the variation between diseased and non-diseased 
subjects. In case of poor reproducibility, the mean value of a series of measurements 
resembles the source signal more closely than any individual measurement.
Uroflowmetry is one of the most widely used non-invasive diagnostic tools in 
patients with LUTS. The most informative uroflow variable is maximum urinary 
flow rate (Qmax) [McConnell, 1995]. Nevertheless, Qmax is not a perfect 
diagnostic tool, and several factors must be kept in mind whenever an uroflow is 
interpreted [Kaplan and Te, 1995]. Firstly, Qmax correlates poorly with the results 
of pressure-flow studies, which are considered the gold standard diagnostic test in 
patients with LUTS. Secondly, Qmax has been shown unreliable if measured on a 
single occasion [Golomb et al., 1992; Meier et al., 1994; Feneley et al., 1996; 
Reynard et al., 1996]. Large variation in Qmax limits its diagnostic power and
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reduces the efficiency of clinical trials that use Qmax as an endpoint. Conversely, 
Matzkin and others [1993] claimed that a single peak flow measurement is 
sufficient. Thirdly, the unfamiliar surrounding in which uroflowmetry is usually 
performed can lead to fear or anxiety when requested to void. As a result, uroflows 
produced at the outpatient department may not be characteristic for the patient’s 
normal voiding behaviour. The use of a home-based portable flowmeter may 
reduce this problem, although patients may have trouble learning to use a portable 
flowmeter. Furthermore, different from standard uroflowmetry at the outpatient 
department, patients do not need to have a full bladder when using a portable 
flowmeter. Owing to differences in bladder filling, additional variation between 
individual flows may be introduced. We evaluated the variability of home-based 
Qmax measurements, and determined the required number of flows as a function 
of the accepted variability.
Methods
All patients enrolled in this study presented with LUTS, suggestive of BOO or 
bladder dysfunction to the University Medical Centre Nijmegen, the Netherlands 
between 1995 and 1997. Patients received routine investigation including 
evaluation of symptoms and quality of life listed on the IPSS, uroflowmetry with 
determination of Qmax and voided volume, measurement of post void residual 
urine volume, ultrasonographic assessment of prostate volume, and pressure flow 
studies with determination of the urethral resistance index (URA). BOO was 
considered to be present if URA > 29 cmH2O [Rollema and Van Mastrigt, 1992]. 
In addition, patients received a home-based portable uroflowmeter (P-flow) to 
produce 12 consecutive flows in their natural habitat and were instructed to apply 
normal voiding behaviour (figure 4.1). The P-flow has been described in detail 
previously [de la Rosette et al., 1996]. In summary, it registers time and volume at 
each moment during voiding. Afterwards, the stored data are transferred to a 
computer to calculate Qmax, total voided volume, mean flow rate, voiding time 
and flow time. A program to assure the quality of the flows is implemented. 
Furthermore, an expert manually inspects all flows and makes corrections if 
necessary. The accuracy of the flow rate measurement is determined by applying 
known artificial flow rates and the error is < 2.5 ml/s.
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Figure 4.1 The P-flow
For the present study, patients were excluded if they previously underwent prostate- 
related treatment, if they were in acute urinary retention, or if they were unable to 
use the P-flow correctly. Flows classified as artefacts after manual and computerised 
inspection were excluded. The use of Qmax is questionable if voided volume is 
small [Drach et al., 1979]. Therefore, we repeated the analyses while excluding 
flows with voided volumes smaller than 150 ml. In order to assess the presence of a 
learning curve while using the device, all analyses were repeated while successively 
excluding the first, the first two and the first three flows of each patient.
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Statistical methods
In general, repeated measurements in the same patient will vary around the true 
mean value, because of measurement error and biological variability [Bland and 
Altman, 1996a]. To quantify the variability between consecutive measurements, 
two or more measurements from a number of subjects are collected. For each 
subject, the standard deviation (SD) of his measurements is calculated. The 
individual SDs (or actually the variances) can be averaged, if we assume that the SD 
is the same for all subjects. This calculation corresponds to a one-way analysis of 
variance, with each patient representing a separate category. To use the within 
subject SD as a measure of variability of a test, the data must be normally 
distributed. In other circumstances, the data can first be transformed, for instance 
by taking the logarithm of each measurement. Subsequently, the transformed data 
are analysed in the same way as described above for the untransformed data.
When diagnosing a man with LUTS, a 5 ml/s over- or under-estimation in Qmax 
has more consequences if the actual Qmax is around 15 ml/s than if it is around 30 
ml/s. Put in other words, 33% deviation (5/15) is of more importance than 17% 
(5/30). It is therefore informative to present the SD expressed as a percentage of the 
subject’s mean Qmax. This parameter, the SD divided by the mean is known as the 
coefficient of variation (CV). The SD in log-transformed values approximates the 
CV, provided the SD is small relative to the mean [Bland and Altman, 1996b].
The CV can be used to calculate a confidence interval (CI) around the estimated 
mean value of each patient. For instance, if the CV is 20% and a patient’s Qmax = 
15 at an initial voiding, his true mean Qmax can be any value between 15 ± 1.96 * 
(20% * 15) = 9 to 21 ml/s. The coefficient 1.96 originates from the characteristic 
property of the normal distribution that 95% of all of its observations are expected 
to fall within a range of ± 1.96 SD from the mean. Increasing the number of 
measurements results in a reduced variability. The variability of mean Qmax based 
on n flows can be calculated by dividing the CV by the square root of n. In the 
example, if the patient has produced ten flows with a mean Qmax of 15 ml/s, the 
true mean Qmax is likely to fall within the interval 15 ± 1.96 * (20% * 15)/a/10 = 
13 to 17 ml/s. If CV is known, the required number of measurements can be 
calculated as a function of the maximum acceptable deviation from mean Qmax.
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Results
Between January 1995 and March 1997, 208 patients used the P-flow. Patient 
characteristics are presented in table 4.1. Eighteen percent of the flows was 
classified as artefacts. Artefacts were uniformly distributed over the 12 flow 
attempts. A total of 2,049 flows was available for analyses, yielding an average of
9.6 valid flows per patient. The total voided volume was < 150 ml in 687 flows.
Table 4.1 Distribution o f patient characteristics
Mean Standard
Centiles
deviation 2.5th 50th 97.5th
Age (years) 62 9 48 62 78
IPSS (0-35) 16 7 5 16 29
Quality of life (0-6) 4 1 0 4 6
Qmax clinic (ml/s) 11 5 4 9 24
Bladder capacity (ml) 260 136 77 243 620
Prostate volume (ml) 39 19 17 32 91
Post void residual urine (ml) 50 102 0 5 360
Urethral resistance index (URA) (cmH2O) 35 20 5 30 88
A wide range of approximately normally distributed Qmax values was observed (1 - 
53 ml/s). Mean Qmax among patients with proven BOO on urodynamic 
investigation was 10 ml/s, mean Qmax among men without obstruction was 15 
ml/s. The individual SD in Qmax was proportional to the individual mean Qmax, 
according to Pearson’s coefficient of correlation of 0.67 (p = 0.00) (figure 4.2). 
Table 4.2 shows the results of the statistical analysis. The average CV was 0.27 
(95% CI: 0.26 - 0.28). Thus, a patient’s mean Qmax may deviate as much as 1.96 
* 27% = 53% from a Qmax measured on a single occasion. For instance, if a single 
Qmax is 15 ml/s, the mean Qmax may be any value between 15 ml/s ±5.3  ml/s =
9.7 to 20.3 ml/s.* The CV while excluding all flows < 150 ml was 0.22 (95% CI: 
0.21 - 0.23). The variability in Qmax hardly changes when excluding the initial 
flows, suggesting that there is no learning curve when first using the P-flow.
* Since 0.27 is relatively large, the approximation of CV is imprecise. The confidence interval limits of a single 
flow lie 42% below and 71% above a single Qmax measurement (e(±L96 *027)).
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Table 4.2 Coefficient o f variation according to volume cutoff point and exclusion o f initial flows
Voided Volume > 0 ml Voided Volume > 150 ml
Learning curve* CV (%) Flows (n) CV (%) Flows (n)
0 27.5 2,049 22.1 1,362
1 27.0 1,841 21.9 1,231
2 27.1 1,634 22.0 1,102
3 27.1 1,427 22.1 973
* Column indicating the number o f initial flows excluded from analysis. For instance, “2” means that the first two 
flows o f each patient were omitted.
CV, coefficient o f variation
mean Qmax (ml/s)
Figure 4.2 Standard deviation in Qmax according to mean Qmax
The average CV was used to calculate the number of flows needed to obtain 
differently sized 95% CIs (figure 4.3). For example, to allow a maximum error in 
mean Qmax of 10% (e.g. 15 ml/s ± 1.5 ml/s) approximately 25 valid flows are 
necessary. The corresponding number of flows while excluding all flows with 
voided volumes below 150 ml is 21. Using figure 4.3, one can easily estimate the 
variability of mean Qmax based on a specified number of flows.
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number of flows 
—O— > 0ml —O— >150 ml
Figure 4.3 Confidence interval limits relative to mean Qmax according to the 
number o f flows
Discussion
This study shows that a single Qmax value may deviate more than 50% from the 
true mean Qmax of a patient. This variation is large relative to the variation 
between obstructed and unobstructed patients. Calculating a mean Qmax of, for 
instance, 25 flows results in a decrease of the deviation from 50% to 10%. The 
results of this study are in agreement with previously reported findings that a single 
(home-based) uroflow measurement is insufficient to describe a patient’s voiding 
pattern [Golomb et al., 1992; Meier et al., 1994; Feneley et al., 1996; Reynard et 
al., 1996]. Meier and colleagues stated that at least 50 flows are required for a 
sufficiently reproducible Qmax measurement. We must be reluctant, however, to 
make judgements about the number of flows required merely based on statistical 
analysis. More important is the amount of uncertainty the patient and his physician 
are willing to accept.
Strictly speaking, the variability in repeated Qmax measurements is not caused by a 
lack of reproducibility. As Qmax really changes between repeated flows, natural
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variation better describes the fluctuations. At the other hand, Qmax is used to 
indicate the presence or absence of BOO, or actually to help decide between 
treatment alternatives. It is reasonable to assume that indications for treatment do 
not change within a period of days. From this perspective, the variation in Qmax 
can be considered as a lack of reproducibility.
Increasing the number of measurements reduces the large variability in Qmax. 
Adjusting for known sources of variation, however, may be a more attractive 
approach. For instance, a circadian rhythm in Qmax has been described [Golomb 
et al., 1992; Witjes et al., 1997b]. In general, flows are relatively weak during the 
night and early morning, and relatively strong during the afternoon and evening. 
The difference between both extremes, however, is less than 2 ml/s on average, and 
standardising Qmax values according to this rhythm had only minor influence on 
the variability in Qmax in our study (results not shown). Another source of 
variation in Qmax consists of a relation between Qmax and voided volume. This 
relation is the topic of chapter 5.
The patients in our study had somewhat more favourable baseline characteristics 
and were less obstructed than most men with LUTS visiting our department. 
Restricting the analyses to sufficiently large flows further excluded a 
disproportionate number of flows from more severely diseased patients. It is 
possible that our results had been different if more flows from obstructed patients 
were included in the study. We repeated the analyses in subgroups based on grade 
of obstruction and indeed found a slight trend towards increased variability among 
more severely obstructed patients. The average CVs were not much different, 
however, ranging between 25% and 31% (results not shown).
The diagnostic value of uroflowmetry is limited when voided volume is small 
[Drach et al., 1979]. The reason for this limited value may be that with small 
voided volumes, the bladder outlet has remained constricted due to psychological 
hesitation and incomplete pelvic floor relaxation. Consequently, the produced 
urinary flow rate is not merely the result of detrusor pressure and prostatic 
obstruction. In our analysis, we found less variability in Qmax if a 150-ml volume 
cutoff was applied. Nevertheless, since a substantial number of flows is excluded, 
using the 150-ml cutoff proves to be less efficient. Including flows of all volumes, 
however, may also prove to be of reduced diagnostic value.
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The use of home flowmetry has three main advantages over office flowmetry. 
Firstly, it may be more comfortable to the patient. Secondly, the hesitation that a 
patient may have when requested to void in the hospital will be minimised, thus 
eliminating a possible “white-coat” influence on micturition. Thirdly, home 
flowmetry supplies the urologist with a large number of time-flow curves, including 
flows produced outside office hours. These data enable the calculation of mean 
parameter values (e.g. Qmax) that reduce the effect of random fluctuation. 
Unfortunately, not all flows produced at home represent the maximum voiding 
capacity of the patient (e.g. before bedtime or after heavy exercise). In fact, one can 
question if a mean Qmax estimate is a valuable parameter in the assessment of men 
with LUTS. If a man is able to void with high Qmax even once, it is unlikely that 
his prostate is permanently obstructing the bladder outlet. Maybe, the highest 
Qmax from a series of flows is therefore better able to predict the grade of 
obstruction than mean Qmax is. We assessed the relation of the mean, the highest 
and the lowest Qmax with the urethral resistance index URA using a linear 
regression model (table 4.3). High URA values indicate obstruction. Mean Qmax 
correlated better with URA than the highest and the lowest Qmax, although it did 
not account for more than 23% of the total variation in URA.
Table 4.3 Relation o f uroflow variables with urethral resistance index
Univariate model Multivariate model
Variable Regression
coefficient P-value
Regression
coefficient P-value
Mean Qmax (ml/s) -1.52 0.00 -2.11 0.04
Highest Qmax (ml/s) -1.19 0.00 -0.09 0.88
Lowest Qmax (ml/s) -1.46 0.00 0.68 0.23
Qmax, maximum urinary flow rate
The ability of flowmetry to discriminate between various causes of LUTS is limited 
in the absence of information on detrusor pressure. Assessing multiple flows does 
not eliminate this problem. In addition, experienced urologists are usually able to 
decide which treatment is best suited for a particular patient irrespective of the 
exact value of Qmax. Therefore, improved variability in Qmax may have little 
bearing on the diagnostic process. When evaluating the natural history or treatment
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outcome of individual patients or groups of patients in clinical trials, however, 
accurate outcome measures are called for. Increasing the number of measurements 
per patient may be a more attractive way to enhance the efficiency of a trial than 
including more patients. In such cases, one should be well aware of the error 
associated with each number of measurements.
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Chapter 5 Volume adjustment o f maximum 
urinary flow rate
Introduction
If the measured value of a source signal differs at repeated occasions, calculation of 
the mean of those measurements is one way to reduce the variability. If it is 
expensive, bothersome or otherwise unattractive to collect repeated measurements, 
adjusting for known sources of variation provides an attractive alternative. If the 
measurement of y  differs according to the value of x and the relation between both 
variables can be quantified, it is possible to calculate the value of y at a standardised 
value of x. This procedure eliminates the effect that x has on y  and thereby reduces 
the variation in y .
Maximum urinary flow rate (Qmax) varies considerably between repeated 
measurements. The initial filling of the bladder is one source of variation in Qmax 
that has received much attention [Von Garrelts, 1957; Siroky et al., 1979; Drach et 
al., 1982; Höfner et al., 1992; Van Mastrigt et al., 1997a]. A large urine volume 
distends the bladder wall and results in more powerful bladder contractions of the 
detrusor muscle [van Mastrigt, 1999]. Because of the fact that initial bladder filling 
is difficult to measure, it is often approximated by voided volume (VV). Thus, 
when flow rates are measured repeatedly in the same individual, large VV tends to 
correspond to high Qmax, and vice versa. In addition to a correlation at the 
individual level, Qmax and VV are also related at a population level. In general, 
patients with small functional bladder capacity will void small volumes. Functional 
bladder capacity is reduced in patients with bladder outlet obstruction (BOO) and 
in patients with bladder hypocontractility [Levin et al., 1990]. Two of the most 
prevalent causes of LUTS, these disorders are also associated with low Qmax. Thus, 
these patients show low Qmax and low VV, compared to patients with LUTS due 
to other causes. The heterogeneity in Qmax between persons can be used in the 
diagnostic process to discriminate between various causes of LUTS. Adjustment for 
VV at population level reduces this heterogeneity and should be avoided.
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Figure 5.1 Illustration o f the possible bias resulting from analysing Qmax - voided 
volume pairs o f several patients collectively. The overall regression line is 
based on a collective analysis ofthe data and is much steeper than that o f 
any ofthe three individual patients.
In summary, the causes of the relation between VV and Qmax are twofold. Firstly, 
an increased filling results in more powerful bladder contractions. This effect 
corresponds to everyday experience. Secondly, patients with BOO or 
hypocontractility of the bladder have a smaller functional bladder volume and a 
reduced force of the urinary stream. For diagnostic purposes, adjustment according 
to the former relation is beneficial, while the latter must remain unchanged. Figure 
5.1 shows the bias that results if the two levels at which VV and Qmax are related 
are not taken into account separately. For a proper adjustment, the solid individual 
regression lines between Qmax and VV must be calculated. Adjustment according 
to the dashed overall regression line incorrectly combines the effects at a population 
level and at individual level. Previous studies did not perform individually based 
regression analysis, and as a result, the relation of VV to Qmax in individual 
persons remains unknown. The fourth international consultation on BPH was 
indeed unable to agree upon a generally accepted method for volume correction of 
Qmax [Koyanagi et al., 1998]. In fact, it was not clear whether the volume
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dependency of Qmax needs to be taken into account at all. To answer this 
question, we studied the relation between VV and Qmax at the individual level and 
at the population level using multilevel regression analysis.
Methods
We evaluated men with LUTS who were referred to the University Medical Centre 
Nijmegen, the Netherlands, between 1995 and 1997. Details of the patients are 
described in chapter 4. It was not possible to determine residual urine with each 
homeflow. Therefore, we were unable to estimate initial bladder filling and studied 
the relation of Qmax with VV instead.
Statistical methods
Throughout the analyses we used logarithmically transformed values of Qmax and 
VV, as these values offered a better fit in the regression models. Linear curves at a 
logarithmic scale correspond to hyperbolic curves at a linear scale.* Throughout the 
text, log(Qmax) is denoted LQ, log(VV) is denoted LV.
Since the available flow measurements are organised in a two-level structure, i.e., 
flows within patients, we fitted two-level regression models. For an extensive 
discussion of these models, see for instance Singer [1998]. In brief, the first level of 
the multilevel analysis models LQ ij, the ith flow from the jth patient, as the sum of 
Qmax from an individual intercept for each patient and a random error associated 
with each flow ( Sij). The second level expresses the individual intercepts as the sum 
of the grand mean of all LQ  and a series of deviances from that grand mean, one 
deviance for each patient. The grand mean is denoted ß0, the deviance for the jth 
patient is denoted u0j . Combining the two levels into one formula gives the simple 
components of variance model:
LQij = (ßo + uoj) + £ij (model 1)
* a • xb = a’ + b • log(x)
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The random errors eij are assumed to be normally distributed with zero mean and 
variance g .^ , the latter indicating the within patient variability in LQ. The 
deviances from the grand mean for each patient ( u0j) are assumed to be normally
distributed with zero mean and variance g2 . This variance indicates the betweenuoj
patient variability in LQ. Model 1 is similar to a traditional one-way fixed effect 
analysis of variance and provides a baseline against which subsequent models can be 
compared.
Next, we added LV to the model (model 2). The regression coefficient ß1 is 
included as a fixed effect, in other words it is the same for all patients. The variance 
g2. now indicates the within patient variability in Qmax after adjustment for LV. 
LV was rescaled to be centred about the mean LV of each patient, by subtracting 
the patient’s mean LV from all his LV measurements. The intercept ( ßo + u0j) 
estimates the mean LQ  conditional on LV being zero.
LQij = (ß0 + u0j) + ß1 ' LVij + eij (model 2)
A further extension of model 2 leads to model 3, in which the slope of the 
regression line between LV and LQ  is included as a random effect. The slope varies 
across patients and was expressed as the sum of the average slope ( ß1) and a series of 
deviances from that average slope, one deviance for each patient ( u1j). The 
individual intercepts are still expressed as the sum of the grand mean of all LQ  ( ßo) 
and a series of deviances (u0j). The u1j ’s together with the u0j ’s are assumed to be 
multivariate normally distributed with zero means, variances g  ^ and g^. , and 
covariance gU01 , the latter representing the correlation between the individual 
intercepts and slopes.
LQij = (ß0 + u0j) + (ß1 + u1j) • LVj + eij (model 3)
Finally, we added interaction terms of LV with age, prostate volume, IPSS, quality 
of life score, residual urine and BOO to model 3 and evaluated the correlation of
72
these terms with the slopes of the individual regression lines. This analysis shows 
whether the heterogeneity in the slopes can be explained by one or more of the 
available patient characteristics.
A visual inspection of the residual plots showed that the assumptions regarding the 
distribution of the error terms were generally satisfied. The goodness of fit of the 
models was evaluated with the residual log likelihood (maximum likelihood 
method). The analyses were performed with Proc Mixed in SAS 6.12 for Windows 
[SAS Institute, 1996].
Results
Between January 1995 and March 1997, 208 patients used the P-flow, producing 
2049 non-artefactual flows for analyses. Figure 5.2 shows the original registrations 
of LQ  versus LV, with individual regression lines of four patients plotted to 
illustrate the different relations for individual persons. The dashed line is the overall 
regression line, which disregards the multilevel structure o f the data. Table 5.1 
shows the results of the three multilevel regression models.
Table 5.1 Results o f the multilevel regression analysis
Model
Regression estimates (standard error)
ßo 2Qp..pij
2
QUoj ß1
2
Q U" u ij
2.423 o.o76 o.156
(o.o28) (o.oo2) (o.o16)
2.423 o.o65 o.157 o.253
(o.o28) (o.oo2) (o.o16) (o.o15)
2.423 o.o52 o.158 o.215 o.o85
(o.o28) (o.oo2) (o.o16) (o.o25) (o.o13)
Res log 
likelihood
(ß o + u 0j) + pij
(ßo + u 0 j) +  ß1 • LVj  + pij 
(ßo +  Uo j) + (ß i +  u i j ) • L Mj +  p ij
-575.161
-435.740
-351.981
Model 1
Mean LQ  in this sample of patients equals 2.423. The variability between patients 
is 0.156, the variability within patients is 0.076. A variance within patients of 0.076 
corresponds to the standard deviation of 0.275 (see chapter 4).
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Figure 5.2 Original registrations o f Qmax and V V  with individual regression lines 
o f a sample ofthe patients to illustrate the relation at an individual level. 
The dashed line shows the relation at the population level.
Model 2
In this model, LV was included as a fixed effect. The residual log likelihood 
reduced markedly compared to model 1 (^2-test, p-value = 0.00). Thus, LV has a 
distinct effect on LQ, and hence VV has a distinct effect on Qmax. The relation 
can be described as Qmax = 2.423 * VV0253. The intercept 2.423 estimates the 
mean LQ  conditional on LV being zero. Because we centred LV at the mean of 
each patient, it indicates a LQ  of 2.423 at each individual’s mean LV. In case we 
had not centred LV, the interpretation of the intercept would be similar for all 
patients as the expected LQ  when logarithm of VV equals zero, i.e., when VV 
equals 1 ml. Firstly, no patient voids only one ml, and thus the intercept would be 
meaningless without centring. Secondly, estimating Qmax at a common VV adjusts 
for the heterogeneity between patients’ average VV, thereby reducing the between 
patient variability in Qmax (figure 5.3). As expected, the between patient variability 
remained constant at 0.157. LV explained ((0.065 - 0.076) / 0.076) = 14% of the 
within patient variability in LQ.
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Figure 5.3 Illustration ofthe effect o f centring at the individual's mean volume. The 
difference in Qmax between the two hypotheticalpatients is much lower at 
a common voided volume o f zero, than at each patient's mean volume. 
Thus, without centring the variability between patients reduces 
considerably.
Model 3
In this model, the slope o f the individual regression lines relating LQ  to LV is 
included as a random effect. The average slope was 0.215, the variance in the slopes 
was 0.085 (p = 0.00). This finding shows that the slope is expected to lie between 
0.215 ± 1.96 * a/0.085 = -0.36 to 0.79 for 95% of the patients. The negative lower 
limit of -0.36 means that Qmax even tends to be lower with increased VV in some 
patients. Having the slopes vary, explained another ((0.052 - 0.065 / 0.065) = 20% 
of the within patient variability in LQ. As expected, the between patient variability 
remained constant at 0.158.
We found a negligible correlation (r = -0.01; p = 0.18) between the slopes and 
intercepts o f the individual patients. In other words, there is no evidence that the 
effect of LV on LQ  differs upon the average LQ  of patients. Similarly, there is no 
evidence for a relation between the slopes and patient age, IPSS, quality of life
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score, prostate volume and residual urine (table 5.2). We did find, however, that 
larger average VV corresponds to a shallower slope. Figure 5.4 is included to show 
the relation between average LV and the slope o f the regression line. The figure is 
based on model 2 with LV included as a fixed effect, and an interaction term added 
between LV and each patient’s average LV. In the graph the dots are the predicted 
mean LQ  for the mean LV of the patient. The points have a slope of 0.63 and the 
lines give the slopes for a sample of the individual patients. At high average LV 
there is no adjustment to be made in that the predicted Qmax does not change very 
much with individual LV. At low average LV a bigger adjustment is made. Adding 
an interaction term between LV and average VV to model 3 in which LV is 
included as a random effect, reduced the variance in the subjects’ slopes from 0.085 
to 0.076. In addition to the interaction effect of average LV, unobstructed patients 
appeared to have steeper regression lines than obstructed patients. Adding 
obstruction grade to the model with average LV already included, reduced the 
variance in the subjects’ slopes from 0.076 to 0.056.
Table 5.2 Regression coefficients o f patient characteristics with individual regression slopes
Regression coefficient P-value
Mean voided volume (ml) -o.372 o.oo
Age (years) o.oo1 o.74
International prostate symptom score (o-35) o.oo2 o.77
Quality of life (o-6) o.oo1 o.58
Prostate volume (ml) -o.oo2 o.16
Post void residual urine (ml) -o.ooo o.44
Urethral resistance index URA (cmH2O) -o.oo5 o.oo
Discussion
This study clarified the relation between Qmax and VV. Different from previous 
studies we used multilevel regression analysis to take the two-level structure of the 
data into account. This type o f analysis enables quantification o f the relation 
between VV and Qmax at an individual level independent of the relation at the 
population level. Also different from most previous studies, we evaluated patients 
with LUTS instead of healthy volunteers. Possibly, the relation between VV and 
Qmax differs between healthy volunteers and patients with LUTS.
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4Figure 5 .4  Relation between mean L V  and the slope o f the individual regression 
lines
Several previous studies addressed the volume dependency of Qmax. In 1957, Von 
Garrelts reported the results of his analysis of the relation between VV and Qmax 
in 125 volunteers without voiding complaints with a maximum o f two flows per 
person. In his report, Von Garrelts speculated about differences in individual 
regression lines. He stated, however, that “owing to the difficulty ... o f obtaining the 
number o f recordings from each person necessary for the [appropriate] analysis ... the 
results from several persons were studied collectively. ” Because of the collective analysis 
the author could not distinguish the two levels at which VV and Qmax are related. 
The ratio of Qmax over the square root of VV that resulted from this study is 
therefore misleading. Nevertheless, it is frequently used as volume independent
77
uroflow parameter. In a separate analysis of our data we used the same naive 
method as Von Garrelts did over 40 years ago and found Qmax to be related to VV 
to the power of 0.41. This result is not much different from VV to the power of 
0.50 that Von Garrelts reported and which corresponds to the square root of VV. 
Had Von Garrelts been able to obtain as many recordings as he thought were 
necessary and had he been able to perform multilevel regression analysis, he might 
well have found results very similar to the ones we presented in our study.
In 1979, Siroky and colleagues constructed a flow rate nomogram to discriminate 
normal from abnormal voiding using Qmax and initial bladder filling. Based on 
collective data of 80 healthy men, mean Qmax was determined in consecutive 
intervals based on bladder filling. A departure from volume-specific mean Qmax 
more than two times the standard deviation was considered to indicate BOO. In 
addition to the inappropriate collective data-analyses, this interpretation of uroflow 
results mistakenly suggests that the prevalence o f BOO is independent o f bladder 
filling. More specifically, it implies that the prevalence is exactly 2.5%.
Drach and colleagues [1982] also constructed a nomogram to discriminate normal 
from abnormal voiding. Their nomogram was adjusted for patient’s age and average 
VV. A relation between Qmax and age results from age-related changes in the 
function of the lower urinary tract. Adjustment for age means adjustment for the 
underlying physiology and will therefore mask true differences between patients. In 
other words, adjustment for age reduces the variability in Qmax between patients 
and is counterproductive for purposes of diagnosis in men with LUTS.
Van Mastrigt et al. [1997a] concluded that the relation between VV and Qmax 
differed according to the average VV and that the heterogeneity may be related to 
irreversible changes in detrusor contractility secondary to BOO. In our present 
study, the slope o f the individual regression line was indeed related to the grade of 
obstruction. Unobstructed patients on average have steeper regression lines than 
obstructed patients. This finding suggest that a change in URA within the same 
individual, for instance by means of treatment, can also be reflected by a change in 
the slope of an individual’s regression line relating Qmax to VV. Whether or not 
the regression slope is sensitive to changes in obstruction grade must be established 
by means of follow-up studies. In theory, if the slope is indeed responsive, it can be 
used in the post-treatment follow-up of patients with LUTS.
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A lowest admissible voided volume of 150 ml is usually advised when using 
uroflowmetry in clinical practice and scientific studies. The main reason for this 
cutoff appears to be a finding by Drach and coworkers [1979] who demonstrated 
that the relation between Qmax and VV could be adequately expressed by a linear 
curve only if volumes above 150 ml are considered. The results of our multilevel 
analysis are in agreement with those of Drach, insofar that at low average VV a 
bigger adjustment must be made (figure 5.3). If enough flows are available for an 
individual patient, however, it is possible to adjust Qmax at any VV, and there is 
no need to ignore flows with small VV.
We conclude that currently used equations and nomograms to adjust Qmax for VV 
yield misleading results. Our analysis showed that the relation between VV and 
Qmax differs between patients and it is therefore inappropriate to use a common 
method of adjustment. The only valid, though impractical option, is to calculate an 
individual regression line for each patient based on repeated uroflow measurements.
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Chapter 6  Variability o f pressure-flow studies
Introduction
The most effective treatment in men with lower urinary tract symptoms (LUTS) 
secondary to bladder outlet obstruction (BOO), is removing the infravesical 
obstruction. Both symptoms and urodynamic effects improve after desobstructive 
therapy. If no obstruction is present, however, chances are small that such therapy 
will be successful. Approximately one third of men with LUTS do not have BOO 
[Abrams, 1994a]. In these cases, detrusor instability or detrusor underactivity is 
often responsible for the symptoms. The pre-treatment diagnostic assessment of 
patients with LUTS therefore aims at estimating the probability that the patient is 
obstructed. Measuring detrusor pressure and urinary flow rate simultaneously, 
enables pressure-flow studies (PFS) to quantify the urethral resistance. Although 
there is yet no consensus on the clinical relevance of precisely grading the amount 
of resistance [McConnell, 1994], PFS are considered the best objective way to 
establish the presence or absence o f BOO. PFS are also used in the follow-up of 
treated patients and to compare treatment modalities in clinical trials.
In order to justify the standard use of PFS as a gold standard test, the test-retest 
variability must be small for practical purposes. Variability of PFS outcomes has 
been the subject of previous studies [Van de Beek et al., 1992; Madsen et al., 1995; 
Rosier et al., 1995; Witjes et al., 1996; Hansen et al., 1997]. The interval between 
test and retest in these studies, however, has been either too short or too long to 
draw definite conclusions. A retest within the same session of testing is not 
representative of the initial test as it does not allow the detrusor muscle to regain 
strength, while stretch receptors in the bladder wall may become less sensitive to 
filling [Ghoniem, 1997]. Furthermore, factors that may be related to the outcome 
of PFS are more similar within a single session than between visits. Some examples 
include the physician carrying out the investigation, the time since the last meal 
and serum hormone levels. Alternatively, a retest 26 weeks or more after the initial 
test cannot preclude systematic changes in urethral resistance or detrusor 
contractility. To assess the variability in PFS, we retested men with LUTS within a 
treatment-free period of four weeks after the initial test, thus preventing important 
changes in the anatomic condition of the lower urinary tract.
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Methods
Patients enrolled in this study visited the Outpatient Department of Urology of the 
University Medical Centre Nijmegen, the Netherlands between October 1997 and 
June 1998 with LUTS suggestive of BOO. All patients received extensive 
diagnostic assessment including PFS. Patients living near our clinic were informed 
about the aim of the study and were asked to be retested within four weeks of the 
initial examination. Patients using a-blocker therapy or other medication that alters 
the function of the lower urinary tract were excluded from the study. Patients who 
experienced severe problems during the initial PFS were not asked to participate.
Each PFS was performed under the same conditions by one of three specialised 
physicians. Before placing the catheters, an instillation gel containing lidocaine and 
antibacterial agents (Farco Pharma, Germany) was applied. An 8F catheter 
mounted with a microtip pressure transducer (MTC, Dräger, Germany) used for 
vesical filling and recording intravesical pressure was placed under sterile 
conditions. Flow parameters, intravesical and abdominal pressures were recorded 
simultaneously during micturition. Abdominal pressure was recorded rectally with 
an 8F microtip sensor catheter. The pressure sensors were calibrated at atmospheric 
pressure before induction. During cystometry, the bladder was filled with saline of 
20°C at a filling speed of 50 ml/minute with the patient in supine position. Filling 
was stopped when the patient expressed a strong urge to void and micturition was 
allowed in standing position. Flow rates were recorded by a rotating disk flowmeter 
(Dantec Urodyn flowmeter, Dantec, Skovlunde, Denmark). All data were digitally 
stored and analysed with an urodynamic analysis program (UIC/BME Research 
Centre, Department of Urology, Nijmegen, the Netherlands). A physician visually 
inspected all computer results, with correction for pressure or flow artefacts. PFS 
were repeated if the results were of poor technical quality. To quantify obstruction, 
the Abrams-Griffiths number (AG-number) was calculated according to AG- 
number = pdetQmax - 2 * Qmax. In this formula, Qmax is the maximum flow rate 
and pdetQmax is the detrusor pressure at maximum flow rate. The International 
Continence Society (ICS) nomogram was used to classify patients [Griffiths et al., 
1997]. AG-numbers above 40 indicate obstruction, AG-numbers between 20 and 
40 are equivocal, and AG-numbers below 20 suggest the absence o f obstruction. 
The analyses were repeated using the urethral resistance factor URA instead of the 
AG-number and Schäfer’s nomogram instead of the ICS nomogram [Schäfer et al., 
1989]. URA values above 29 cmH2O represent obstruction [Rollema and van
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Mastrigt, 1992]. The results of both PFS sessions were evaluated independently. 
The presence o f systematic changes in urethral resistance was evaluated by 
calculating the mean difference in AG-number between the patients’ first and 
second visits, and the null hypothesis o f no difference was tested with a paired 
sample t-test.
Statistical methods
To quantify the variability between consecutive measurements, the SD of repeated 
measurements in the same subject is calculated. The individual SDs (or actually the 
variances) can be averaged, if we assume that the SD is the same for all subjects. To 
test this assumption, we assessed whether the variability was proportional to the size 
of the measurement by plotting the individual SDs against their associated mean 
values and calculating the coefficient of regression. In addition, the relation of the 
individual SDs with patient age, prostate volume, Qmax, voided volume, post-void 
residual urine, IPSS, quality of life and the period between visits was assessed using 
regression analysis. The average SD can be used to calculate a confidence interval 
around the estimated mean o f each patient. For instance, if  the average within 
patient SD is 4 and the AG-number determined with PFS of a particular patient is 
30, the true mean AG-number of this patient can be any value between 30 ± 1.96 * 
4 = 22 to 38. To describe the clinical relevance of the variability in PFS results, we 
calculated the percentage o f patients that moved from one category o f obstruction 
at the first examination to another category at the second examination.
Results
Eighty-nine patients were included in this study. Table 6.1 shows a summary of the 
patient characteristics. All patients were retested within four weeks of the first visit. 
Table 6.2 shows the characteristics of both PFS. A visual inspection of the 
distribution of AG-number and URA showed that a normal distribution could be 
assumed for these variables. No significant difference was observed in filling and 
voiding parameters between both visits. At the first visit, 33% of the patients was 
unobstructed, 29% was obstructed, and the remaining 38% had equivocal results. 
The corresponding percentages at the second visit were 40%, 26% and 34% (X = 
1.2; p = 0.55). In conclusion, there is no evidence of a systematic change between 
both visits.
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Table 6.1 Summary o f clinical parameters
Mean Standard
Centiles
deviation 2.5th 50th 97.5th
Age (years) 65 8 48 65 79
IPSS (0-35) 15 8 1 14 31
Quality of life (0-6) 3 1 0 3 6
Prostate volume (ml) 36 17 15 32 83
Qmax (free flow) (ml/s) 13 7 4 12 30
Voided volume (free flow) (ml) 248 144 67 229 622
Post void residual urine (free flow) (ml) 51 86 0 10 280
Test-retest interval (days) 14 5 6 13 25
IPSS, International Prostate Symptom Score; Qmax, maximum urinary flow rate
Table 6.2 Results o f pressure flow studies
First visit Second visit
- P-value Average within
Mean SD Mean SD patient SD
Cystometric capacity (ml) 451 140 438 140 0.25 66
Qmax (ml/s) 9 5 9 5 0.71 2
pdetQmax (cmH2O) 45 19 45 20 0.70 12
Abram-Griffiths-number (cmH2O) 28 26 28 25 0.81 14
URA (cmH2O) 28 14 28 14 0.82 7
SD, standard deviation; Qmax, maximum urinary flow rate; pdetQmax, detrusor pressure at maximum flow rate
Figure 6.1 plots the absolute difference per subject between visit one and visit two 
against the associated average AG-numbers, which is equivalent to a SD versus 
mean plot when there are two measurements per subject. The graph shows that the 
difference between both AG-numbers ranges between 0 and 50 cmH2O and does 
not depend on the (average) size o f the measurement. In other words, there is no 
evidence that the error differs between obstructed and unobstructed patients. 
Furthermore, no important relation could be detected between the spread in AG- 
number and any clinical variable, other than a weak relation with the time between 
visits (results not shown).
The average within patient SD was 14 cmH2O (95% CI: 12 - 16). This finding 
means that the difference between a patient’s measured AG-number and his true 
mean AG-number may be as large as 1.96 * 14 = 27 cmH2O. Thus, if a patient’s 
AG-number is 30 cmH2O at the first visit, his true mean value can be anywhere
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between 3 and 57 cmH2O. The average SD in URA was 7 cmH2O. The average 
SD in pdetQmax was 12 cmH2O, that in Qmax was 2 ml/s.
Based on the ICS provisional nomogram, 39% of the patients changed at least one 
category of obstruction and 3% changed from definitely obstructed to definitely 
unobstructed or vice versa (figure 6.2 and table 6.3). The majority of changers had 
equivocal results at the first visit. Based on Schäfer’s classification of obstruction, 
63% of the patients changed at least one category, and 11% changed two or more 
categories.
mean AG-number (cmH2O)
Figure 6.1 Individual absolute differences in AG-number plotted against the 
associated mean
Table 6.3 Number (%) o f patients per obstruction category according to the International Continence
Society nomogram at the first and second visit
Result at first visit
Result at second visit
Unobstructed Equivocal Obstructed
Unobstructed 21 (72) 7(24) 1 (4)
Equivocal 13 (38) 16 (47) 5(15)
Obstructed 2 (8 ) 7 (27) 17 (65)
Percentages indicate the proportion o f patients in each category at the second visit conditional on the result at 
the first visit
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Figure 6.2 Change in pressure-flow study result plotted on the International 
Continence Society provisional nomogram
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Discussion
A pressure flow study is considered the gold standard test in the assessment of men 
with LUTS and is often used to objectively evaluate treatment. Nevertheless, 
standard use of PFS is not commonly accepted. Those who oppose standard use 
claim that its additional value to identify obstruction does not compensate for the 
associated morbidity, physician time and expenses [McConnell, 1994]. In a 
previous study, Kortmann et al. [1999] showed that the morbidity associated with 
PFS is low. In the present study, we evaluated the variability ofPFS outcome.
A considerable deviation of approximately 27 cmH2O may exist between the 
observed and the mean AG-number of a patient with LUTS. This variability is also 
reflected in the 39% of patients moving between categories of obstruction of the 
ICS nomogram between visits. As AG-number is determined by pdetQmax and 
Qmax, also its variance is determined by the variances of Qmax and pdetQmax. 
The variability in AG-number was influenced more by variability in pressure than 
by variability in flow (table 6.2).
Hansen et al. [1999] recently investigated the short-time reproducibility of 
pressure-flow studies. In 20 patients, they performed four pressure-flow studies in 
two sessions within a month. Using Qmax and pdetQmax to quantify the degree of 
obstruction, 30% of the patients shifted group of obstruction of the ICS 
nomogram between the examinations. This result is in the same general range as 
the 39% of patients that changed in our study.
In another study, Hansen et al. [1997] performed two sequential transurethral 
pressure-flow recordings were performed in a single session in 49 men with LUTS. 
A systematic change in various pressure-flow parameters was observed but no result 
was given for an obstructive index like AG-number or URA. Using the ICS 
nomogram, 12% of the patients changed category of obstruction at the second 
voiding.
2 2 2
* The variance in AG-number is equal to c  pdetQmax + 4 • o Qmax - 4 • covariance(pdetQmax,Qmax), with c
indicating the variance.
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In a previous study from our department, Rosier and coworkers [1995] studied the 
variability of pressure flow parameters in two sequential voidings in a single session. 
Individual differences between the two voidings larger than one Schäfer class of 
obstruction were found in less than 20% of the patients. Performing test and retest 
within a single session, however, resulted in a similar testing environment o f both 
examinations, and thus eliminated some sources of variability. Moreover, systematic 
changes in the sensitivity o f the stretch receptors in the bladder wall and the 
contraction strength of the detrusor muscle may have occurred.
Witjes et al. [1996] assessed the variability of PFS outcome after a treatment free 
interval of 26 weeks. Owing to growth of the prostate, an increase in urethral 
resistance can be expected during this period. There was indeed some evidence of 
systematic changes in urethral resistance within subgroups of obstruction, although 
these changes can readily be explained by regression to the mean as well. In the 
study by Witjes and others, forty-four percent of the patients changed at least one 
ICS category of obstruction; seven percent changed from definitely obstructed to 
definitely unobstructed or vice versa. In an unpublished re-analysis o f these data, 
the within patient SD in AG-number was 15 cmH2O [Witjes, personal communi­
cation].
Madsen et al. [1995] addressed the variability of transurethral PFS outcome in a 
small sample of seven patients, who were retested within the same session. None of 
the patients was urodynamically unobstructed and all but one were obstructed. One 
patient changed category at the second measurement. Although insufficient 
quantitative results are reported for easy comparison, we agree with the conclusions 
o f these authors that a single pressure-flow curve is o f limited value due to 
considerable within patient variation of the test.
Van de Beek and colleagues [1992] studied variability of PFS outcome in 90 
patients with LUTS, but did not state the test-retest interval. The authors reported 
a Pearson’s correlation coefficient as high as 0.95 for two consecutive URA 
measurements, purportedly indicating good reproducibility. The coefficient of 
correlation, however, has limited value in assessing the reproducibility of individual 
outcomes. Indeed, in contrast to their reported high correlation, the authors found 
that in more than 30% of the cases the Schäfer obstruction class differed between 
the first and the second voiding.
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Many randomised controlled trials (RCTs) have been conducted in men with 
LUTS with urodynamic outcome variables [Chapple et al., 1992; Chapple et al., 
1994; Eri and Tveter, 1993a; Eri and Tveter, 1993b; Hedlund and Andersson, 
1988; Kirby et al., 1987; Martorana et al., 1987; Rollema et al., 1991; Stott and 
Abrams, 1991; Tammela and Kontturi, 1995]. The outcomes in the placebo arm of 
RCTs can be used to assess the variability o f PFS, if  an unchanged anatomic 
condition of the lower urinary tract can be assumed. Bosch [1997] provided a 
review o f urodynamic responses to placebo therapy. The interval between test and 
retest in most of these RCTs, however, is six months or more. In addition, many 
studies are hampered by a small study size and usually the results are restricted to 
systematic changes between baseline and follow-up. Few reports mention individual 
variability in an obstructive index. Nevertheless, even if systematic changes between 
consecutive tests are absent, that is, at a group level the results of both tests are 
similar, considerable changes may be present at an individual level. Therefore, it is 
not sufficient to show a small and “statistically insignificant” difference in PFS 
results between consecutive tests in order to draw reassuring conclusions regarding 
the variability of test results. Instead, an evaluation of intra-individual changes is 
needed.
Studies on the variability in PFS outcomes conducted in the placebo arm of a RCT 
use patients who are scheduled for treatment, whereas PFS are in fact often used to 
indicate which patient needs treatment. As a result, RCTs comprise relatively few 
unobstructive patients, making generalisation of the results to a clinical population 
of men presenting to an urologist with LUTS difficult. On the other hand, our 
evaluation o f patients with all grades o f obstruction did not show different 
variability for obstructed patients and unobstructed patients.
Variability in test results can be caused by biological variability and by 
measurement error. Technical problems may cause measurement error in PFS 
outcome. A possible reason for measurement error is pressing the micro-tip 
catheters against the bladder or rectum wall. The contact with bladder or rectal 
tissue induces irregularities in pressure measurement. Thus being more prone to 
artefacts, this type of catheters may increase the variability within subjects 
compared to fluid-filled balloon catheters. In order to test the latter hypothesis, the 
present study must be repeated with balloon catheters. Similarly, transurethral
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pressure measurement may be different from a suprapubic method. It is important 
to repeat PFS if  technical quality is poor. We had to repeat voidings in the same 
session in five patients. While assuring PFS of high quality, these retests may have 
influenced our results.
Measurement error may also be due to difficulties in reading PFS recordings. There 
may be more than one potential Qmax value, with different corresponding detrusor 
pressures. Furthermore, the methods used by computer programs to exclude 
artefactual high initial flow rates or sharply peaking flow rates and detrusor 
pressures are not always adequate nor is there consensus on manual artefact 
correction. Nevertheless, Tammela and coworkers [1999] recently reported 
excellent agreement between the pressure-flow readings o f various observers 
compared to a blinded central reader. The issue of within and between observer 
variability in the interpretation ofPFS is extensively discussed in chapter 7.
A four-week period between repeated PFS as applied in our study is likely to 
exclude important changes in the anatomic condition o f the lower urinary tract. 
This period is also in accordance with most questionnaires assessing urinary 
symptoms, which inquire about symptoms experienced during the previous month. 
In addition, systematic changes and similarities in the test environment resulting 
from performing two tests in a single session were prevented.
The present study was conducted to describe the total variability present in 
everyday urological practice, not to assess specific causes of variation. Nevertheless, 
we observed a small increase in variation with a prolonged interval between visits. 
This finding suggests that some factors influencing PFS outcome change over 
relatively short periods of days or weeks. Fluctuations in PFS outcome may be 
caused by dynamic changes in prostatic smooth muscle tone and bladder response 
to rapidly changing neurological stimuli. Ghoniem [1997] further suggested that 
the presence or absence o f residual urine and the individual variability in 
responding to the test environment contribute to variable urodynamic results. 
Possibly, patients were more relaxed at the second visit as they were already familiar 
with the testing procedure, thus preventing inhibitory sphincter reflexes. Circadian 
changes, as have been described for free uroflowmetry, may also be responsible for 
some of the variability in PFS outcomes. Further investigations may help to identify
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variance components, and possibly to account for these components in decreasing 
the variability ofPFS outcome.
It has been suggested that various methods o f analysis score differently on 
reproducibility [van Mastrigt and Griffiths, 1997]. In our study, the average SD in 
AG-number was 14 cmH2O, and in URA 7 cmH2O. As both indices are derived 
from Qmax and pdetQmax, the lower variability of URA probably stems from the 
different scales o f the indices. Whereas AG-number theoretically ranges between 
plus and minus infinity, URA can only take on non-negative values. When 
comparing their reproducibility, it is thus important to take the scale at which 
obstruction parameters are measured into account.
It is well known that PFS provide valuable information about the function of the 
lower urinary tract. Nevertheless, we found a considerable variability in the results 
of single PFS. Neither a numerical interpretation of PFS results nor a classification 
into obstruction categories provides the physician and his patient with an 
unambiguous test result. In some urodynamic centres the large variation in PFS 
results is already recognised, and a second and sometimes third PFS are performed 
if the first was not conclusive. This practice, however, brings forth other problems: 
how many PFS are sufficient? Are the results of multiple PFS best summarised by 
their average obstruction grade, or is the lowest value more informative? W hat is 
the most valid, yet practical moment to repeat testing? These questions remain 
unanswered. Therefore, we conclude that PFS cannot serve as a gold standard in 
the diagnosis of patients with LUTS.
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Chapter 7  Within and between observer 
variation in pressure-flow studies
Introduction
A pressure-flow study is often considered the gold standard in the diagnosis of men 
with lower urinary tract symptom (LUTS), suggestive of bladder outlet obstruction 
(BOO). Nevertheless, large variation exists between repeated pressure-flow studies 
(PFS) of a single patient. In the previous chapter, we showed that almost 40% of 
the patients undergoing PFS changed at least one class on the obstruction 
nomogram of the International Continence Society (ICS) when retested within 
four weeks of an initial evaluation. Although it is unlikely that the differing results 
are due to substantial growth of the prostate within a period of four weeks, the 
fluctuations may be caused by dynamic changes in prostatic smooth muscle tone 
and bladder response to rapidly changing neurological stimuli. Therefore, real 
changes in the condition of the lower urinary tract may be responsible for the 
variability in PFS outcome. Alternatively, discrepancies in the interpretation of PFS 
between physicians and between repeated readings by the same physician may be 
responsible for part of the variation. Two abstracts have been published that present 
the variability in the interpretation of PFS parameters [Donovan et al., 1994; 
Kirschner et al., 1994]. Unfortunately, both reports provide insufficient data to 
verify the results. Therefore, a study to evaluate the within and between observer 
variation in the interpretation ofPFS was conducted.
Methods
PFS were performed at the University Medical Centre Nijmegen, the Netherlands 
(centre 1) and at the University Hospital of Copenhagen, Herlev, Denmark (centre 
2). The methods of performing PFS used in centre 1 have been described in chapter 
6. The methods used in centre 2 were mostly similar. Different from centre 1, the 
bladder was emptied using a 14F LoFric catheter. An 8F double lumen cystometry 
catheter was used for bladder filling and intravesical pressure recording, and an 8F
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balloon catheter used for rectal pressure measurement. External transducers were 
fixed at the upper border of the symphysis pubis. Urodyn 2000 hard- and software 
were used.
In each centre, 100 consecutive pre-treatment PFS were randomly selected. Black- 
and-white photocopies o f the 200 PFS were distributed to three experienced 
observers from each centre. An example of a PFS output is shown in figure 7.1. 
International standards on the analysis of PFS were appended. Each observer was 
asked to indicate maximum flow rate (Qmax) and the corresponding detrusor 
pressure at maximum flow rate (pdetQmax). As advocated by the ICS, the Abrams- 
Griffiths number (AG-number) was calculated to quantify obstruction according to 
AG-number = pdetQmax - 2 * Qmax [Griffiths et al., 1997]. AG-numbers above 
40 indicate obstruction, AG-numbers between 20 and 40 are equivocal, and AG- 
numbers below 20 indicate the absence of obstruction. After the observers returned 
their analyses, they received the same 200 PFS prints in a different order and we 
asked them to redo the analyses.
100 ....................................................... ;■ ■ ;.................................................... !............ !............¡ ■ ........................................................
pdetr
cmH20
-10
30
........... ;........... ;............
■ " / ............  ...............^
pdetQmax
Flow
ml/s Qmax
0
.......\ ..................................
Voi
AJO ........... - .........—  ■ : ■ ......... ...............
ml.
min
0
0
...........................................................
10
Figure 7.1 Example o f PFS output
Statistical methods
When PFS of consecutive patients are repeatedly analysed by multiple observers, 
three factors affect the outcome of each PFS. Firstly, variation exists between 
patients in the condition of their lower urinary tract. Secondly, observers differ in 
their respective ways of interpreting the same PFS. Thirdly, variation occurs 
between multiple analyses of a single PFS by the same observer. We used regression
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analysis with random effects to estimate the respective components of variance. We 
assumed that the observations AGsoh, the hth (h = 1 ,2) reading of AG-number of 
observer o (o = 1, 2, 3 ,..., 6) on patient s (s = 1, 2, 3 ,..., 200), follow the model:
A G soh a  +  b s +  c o +  s  soh
a = the overall mean of all AGsoh readings
bs = the random effects for the subjects (one random effect for each subject). The 
200 patients included in this study are regarded as a sample from a large population 
of patients. Each patient has an additive effect from the mean AG-number of all 
patients. The bs are assumed to be independently and normally distributed with 
zero mean and variance g2 . This variance represents the natural variation between 
patients.
co = the random effects for the observers (one random effect for each observer). 
The six observers are regarded as a sample from a large population of observers, 
each having an additive effect from the mean effect of all observers. The co are 
assumed to be independently and normally distributed with zero mean and variance 
g2 . This variance can be interpreted as the variation between observers.
s soh = the measurement errors. These errors are the residuals that remain after 
accounting for the effects of the observers and the subjects. The s soh are assumed to 
be independently and normally distributed with zero mean and variance g2 . This
* The term random effects in the context of analysis o f variance is used to denote factors with levels that were 
not deliberately arranged by the experimenter, but which were sampled from a population of possible levels 
instead. For example, since we are interested in the effect that various observers have on the quantification of 
BOO, we selected a sample of all possible observers to estimate the variance in AG-number that is attributable 
to differences between observers. If we were to repeat the study, it is unlikely that we would select the same 
observers again. By contrast, if we want to know the effect of alpha-blocking agents on AG-number, we would 
always arrange a few fixed groups, for instance tamsulosin, terazosin, and alfuzosin. The distinction between 
fixed and random effects is that the variation in the levels o f random factors is assumed to be representative of 
the variation of the entire population of possible levels. The variation in the levels of fixed factors is instead 
considered to be arbitrarily determined by the investigator (the investigator can make the levels o f a fixed 
factor vary as little or as much as desired). Therefore, the variation of a fixed factor cannot be used to estimate 
its population variance.
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variance represents the variation within observers after accounting for the variation 
between patients and observers. We initially assumed that g2 was the same for all 
observers and for both readings of each observer. Some observers, however, are 
more experienced in rating PFS than others. Furthermore, a second evaluation may 
be performed with different accuracy than the initial one. Therefore, we fitted a 
second model in which we let [g^  ^  g^ ]  ^  [g^  ^  g^ ]  for all o ^  p or h ^  i. In 
other words, every observer has two kinds of residuals, one for the first reading and 
one for the second reading. For ease in interpretation, we present standard 
deviations (SD = variance ) throughout the results. The analyses were performed 
using Proc Mixed with restricted maximum likelihood estimators in SAS 6.12 for 
Windows [SAS Institute, 1996].
Results
Table 7.1 shows the results o f the PFS analyses stratified by observer. There was 
some evidence of a systematic difference between the first and the second reading, 
as five out of six observers on average judged the PFS to be more obstructed in the 
second reading than in the first one. Although associated with small p-values, these 
systematic changes were generally small and of little clinical relevance.
Table 7.1 Results o f two times 200 PFS analyses, stratified by observer
Observer
1 2 3 4 5 6
AG-number 1st reading (cmH2O) 48.6 51.9 50.0 55.1 55.2 57.1
AG-number 2nd reading (cmH2O) 50.4 51.5 50.2 59.2 55.3 58.9
Difference -1.8 0.3 -0.2 -4.1 -0.1 -1.8
P-value 0.03 0.64 0.83 0.00 0.88 0.02
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Table 7.2 Parameter estimates from model 1
Description Estimate (cmH2O) Model term
Overall mean AG-number 53.6 a
rr
Between patient SD 29.3 A/Ob
rr
Between observer SD 3.7 V °c
Within observer SD 10.0
rr
1 2 2
Between and within observer SD combined 10.7 V°c + OE
Table 7.2 shows the regression estimates of model 1. The mean AG-number was 
53.6 cmH2O, the SD between patients was 29.3 cmH2O. The between observer SD 
was 3.7 cmH2O, the within observer SD was 10.0 cmH2O. The interpretation of 
these results is as follows:
Suppose the output of a PFS of subject s is shown to observer o. This observer will 
estimate the AG-number anywhere in the interval a + bs + co ± 1.96^ g2  = 53.6 + 
bs + co ± 1.96 * 10.0 cmH2O. In the formula, bs indicates the random effect for 
subject s, co indicates the random effect for observer o, and the multiplication 
factor 1.96 originates from the characteristic property of the normal distribution 
that 95% of all of its observations are expected to fall within the range of ± 1.96 SD 
from the mean. Thus, the subjectivity of the determination of AG-number is 
depicted by an interval as wide as 39.2 cmH2O (±1.96 * 10.0) in which a single 
observer may estimate the AG-number of a PFS output.
If the PFS of subject s is shown to a randomly selected observer, the estimated AG- 
number will fall in the interval a + bs ± 1.96^ g2 + g2 = 53.6 + bs ± 1.96 * 10.7 
cmH2O. This interval is only slightly larger than the interval of each specific 
observer. Thus, given the large variation within an observer, the variation between 
observers is of minor importance.
If two randomly selected observers interpret the same PFS, the difference between 
the estimated AG-numbers can be as large as ± 1.96 *V 2*^/g\  + g2 = 2.77 * 10.7 
= 30 cmH2O. The multiplication factor -,¡2 accounts for the variances associated 
with the estimation ofAG-number ofboth observers.
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Table 7.3 shows the estimates of the variance within observers derived from model 
2. Model 2 provided a better fit to the data than model 1 did, considering the 
change in -2 residual log likelihood. The parameter estimates for a, V o2 and V g2 in 
model 2 did not change compared to model 1. The estimated within observer SDs 
V 02,oh, however, ranged between 7.1 cmH2O and 14.0 cmH2O across the six 
observers and two readings. Thus, some observers are indeed more consistent in 
reading PFS output than others. Four observers were more consistent at the 
analyses of the first set of PFS and two observers performed better at the second set.
Table 7.3 Within observer standard deviation stratified by observer (1, 2,..., 6) and reading (1, 2) from
model 2
Observer Estimate (cmH2O) Model term
One (8.8; 11.1) V a21,1 ; V a21, 2
Two (8.8; 8.3) V a22, 1 ; V a22,2
Three (12.7; 14.0) V a23,1; V a23, 2
Four (9.1; 10.1) V a24,1; V a24,2
Five (8.1; 10.7) V a25,1; V a25,2
Six (10.0; 7.1) V a26,1; V a26,2
Discussion
Treatment in patients with LUTS usually aims at relieving the obstruction of the 
bladder outlet. Decisions about desobstructive treatment in patients with LUTS are 
based on a large number of diagnostic tests. PFS are considered the gold standard 
test in patients with LUTS. Contrary to common belief, however, our study 
showed that PFS do not objectively quantify the grade of obstruction. Instead, the 
result of PFS is to a large degree determined by the interpretation of the physician. 
The combined within and between observer SD in AG-number of 10.7 cmH2O 
indicates that the same patient may well be considered obstructed by one observer 
and unobstructed by another. In actual practice the variation in interpretation may
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even be more pronounced than estimated in our study, as it is likely that observers 
perform better when involved in research than during their daily duties.
We found that the variation between observers was small relative to the variation 
within a single observer. If two observers both have large variation in their 
interpretations, their respective average results need not be far apart. It should be 
noted, however, that we estimated the between observer SD while accounting for 
the variation within observers. In practice, the within and between observer 
variation act simultaneously. The combined SD in our study was 10.7 cmH2O. 
The difference between predicted AG-numbers of the same PFS by two observers 
may be as large as 30 cmH2O.
Several problems with the interpretation of PFS may be responsible for the 
discrepancies between multiple readings of the same PFS. Firstly, technical 
disturbance may cause the baseline of the detrusor pressure to shift. The observer 
must interpret these baseline changes appropriately and adjust the entire pressure 
graph accordingly upward or downward if necessary. Probably, the baseline 
adjustment is applied inconsistently. Secondly, the resolution of the prints may 
have been insufficient for exact reading of Qmax and pdetQmax. The problem of 
low resolution can be addressed by improved printing quality and computer-aided 
reading of Qmax and pdetQmax. Thirdly, it can be difficult to determine whether 
a sharp peak in flow is artefactual (figure 7.2). Fourthly, problems arise with two 
potential Qmax points in the flowcurve. The accompanying detrusor pressures of 
both points in the flowcurve can be very different, resulting in a different degree of 
obstruction (figure 7.3). This problem explains the larger variation in pdetQmax 
compared with the variation in Qmax.
We can rid ourselves of variation between multiple readings by reverting to uniform 
computerised analysis of PFS data. Currently used software for automated analysis, 
however, is not capable of detecting all artefacts or to make relevant corrections. 
Only 60% of all PFS tracings are free of artefacts [Donovan et al., 1994]. 
Therefore, the ICS-“BPH”-Study Group stated that automated computer analysis 
today is not acceptable as substitute for careful inspection and manual graphical 
control.
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Figure 7.2 Drawing o f uroflowmetry: what is Qmax?
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Figure 7.3 Drawing o f pressure-flow study: what is Qmax and what is pdetQmax?
100
Some urodynamicists have tried to come up with international standards to analyse 
PFS and grade of obstruction. Until now, these efforts have not resulted in uniform 
PFS analysis. It is important that everyone involved in urodynamics receive proper 
training and that they become familiar with the theoretical background, technical 
aspects and possible complications of PFS. Some observers are more experienced in 
interpreting PFS than others, and are therefore likely to be more consistent. A more 
consistent interpretation is reflected by a lower within observer variation. New 
guidelines may include a maximum within observer variation.
In conclusion, PFS can provide us with important information about the condition 
of the lower urinary tract. We should bear in mind, however, that the 
interpretation of the physician has much influence on the result of the 
investigation. We must make every effort to minimise the effect of physician 
interpretation on the outcome of PFS.
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Part 3 
Validity

Chapter 8 Object and methods of diagnostic 
research
Introduction
Even if the reproducibility of a diagnostic test is excellent, the test is useless if it 
does not correlate well with the true disease. A validity study may therefore not be 
omitted in the evaluation of diagnostic tests. Any study design includes two distinct 
stages. Firstly, the object of the study is formulated. Which criteria must a 
diagnostic test fulfil in order to be valuable? This stage is called the ontological 
stage. Secondly, the methods of the study are designed. Which empirical data do we 
need to evaluate a diagnostic test and how do we analyse these data? This stage is 
called the epistemological stage. In this chapter, we discuss the prevailing object and 
methods of diagnostic research. Chapter 10 addresses diagnostic research in the 
absence of a gold standard.
The Latin word doctor means teacher. Accordingly, one of the doctor’s main tasks 
is to teach his patients, he should bring knowledge to them. This knowledge 
consists of the particulars of the disease at issue: what is the nature of the disease, 
what is its cause, what will its future course be like, and most importantly, how can 
this be altered by therapeutic intervention. The answers to this type of 
particularistic questions, regarding an individual instance of disease, are called 
gnosis. Gnostic questions are unanswerable. A physician will never be able to tell 
the ultimate truth about the causes of disease in a particular patient nor about its 
future course. Because of the inability to answer them, gnostic questions are 
reformulated: in patients like this one (given a number of characteristics), how 
often is disease D present, how often does substance S play a critical role in the 
causation of D, and how often is treatment T  successful in curing D? These 
questions are about the abstract, about what is true in general and can be answered 
with scientific research.
Science produces abstract knowledge. Abstract knowledge, in contrast to 
particularistic facts, is devoid of time and place. We use abstract knowledge to make
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inference towards gnosis, towards particularistic knowledge in individual patients. 
Given the above, it follows that the object of diagnostic research is not the answer 
of a specific gnostic question. Rather, an estimation of the prevalence of a disease 
conditional on a set of diagnostic test results is the ultimate result of diagnostic 
research [Miettinen, 1998]. The extent to which a particular test or set of tests 
amounts to this probability helps to decide which tests can be used in diagnostic 
practice. The traditional methods to evaluate diagnostic tests are described 
hereafter, focussing on the diagnosis of men with lower urinary tract symptoms 
(LUTS) suggestive of bladder outlet obstruction (BOO).
The probability of a test result in diseased and non-diseased subjects
The most familiar way to assess the value of a diagnostic test is by comparing the 
test result with that of a gold standard test in a “2 by 2” table (table 8.1). The 
sensitivity (Se) of the test can be calculated as the probability of a positive test in 
diseased (a/(a+c)) and the specificity (Sp) as the probability of a negative test in 
non-diseased (d/(b+d)).
Table 8.1 The “2 by 2” table shows the number o f patients stratified by test result and presence or
absence o f disease as measured by a “gold standard” diagnostic test.
Disease
present absent
Test
positive a b a + b
negative c d c + d
a + c b + d a + b + c + d
Sensitivity = a / (a + c)
Specificity = d / (b + d)
LR+ = Se / (1-Sp) = (a / (a + c)) / (b / (b + d)) 
LR- = (1-Se) / Sp = (c / (a + c)) / (d / (b + d))
Bladder outlet obstruction
present absent
Qmax
< 15 ml/s 82 33 115
> 15 ml/s 18 67 85
100 100 200
Sensitivity = 8 2 / 100 = 82% 
Specificity = 67 /100 = 67% 
LR+ = (82/100) / (33/100) = 2.5 
LR- = (18/100)/(67/100) = 0.3
Qmax, maximum urinary flow rate; LR+, Likelihood ratio o f a positive test; LR-, Likelihood ratio o f a negative test
For instance, maximum urinary flow rate (Qmax) below 15 ml/s is considered a 
positive test result in patients with LUTS to identify BOO. From table 8.1, Se and 
Sp are estimated to be 82% and 67%, respectively. These estimates mean that low
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Qmax is 2.5 times more likely in obstructed patients than in unobstructed patients 
(Likelihood Ratio of a positive test = LR+ = Se/(1-Sp)) and high Qmax is 0.3 times 
as likely in obstructed patients compared with unobstructed patients (Likelihood 
Ratio of a negative test = LR- = (1-Se)/Sp). Clearly, a good test has a high LR+ and 
a low LR-.
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Figure 8.1 Distribution o f Qmax in obstructed and unobstructed patients with 
LUTS. Moving the cutoff point changes sensitivity and specificity.
The “2 by 2” table is based on the distribution of test results among diseased and 
non-diseased subjects and the choice of a particular cutoff point (figure 8.1). 
Changing the cutoff point results in different Se and Sp, and consequently in 
different LR+ and LR-. In order to evaluate a diagnostic test independent of 
subjectively chosen cutoff points, a receiver operating characteristic (ROC) curve 
can be plotted and its associated area under the curve (AUC) can be calculated 
[Hanley and McNeil, 1982]. The ROC-curve is based on the entire range of Se and 
Sp at various cutoff points (figure 8.2). The curve plots the percentage of true 
positives (Se) against the percentage of false positives (1-Sp) and thus summarises 
the difference in distribution of test results between diseased and non-diseased
sensitivity = 18% sensitivity = 82% sensitivity = 98%
specificity = 97% specificity = 67% specificity = 17%
I
T
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subjects. The AUC is a measure of the diagnostic capacity of the test. In case of 
completely overlapping distributions, the percentage true positives equals the 
percentage false positive at each cutoff. This situation corresponds to a straight 
diagonal line in the ROC-curve and a corresponding AUC = 0.5. Alternatively, a 
perfect discriminatory test with two completely separate distributions results in an 
AUC = 1.0. W ith the AUC, the diagnostic ability of different tests can easily be 
compared.
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Figure 8.2 Receiver operating characteristic (ROC) curve. Each point in the curve 
represents a combination o f sensitivity and specificity that corresponds to 
a specific cutoff value in the test result (e.g. Qmax <15 ml/s).
A common misbelieve is that at each given cutoff point, Se and Sp are stable 
characteristics inherent to a test. It is true that Se and Sp do not depend on the 
prevalence of disease per se. The value of diagnostic tests, however, strongly 
depends on the clinical profile of the study population [Moons et al., 1997]. The 
distribution of Qmax values, for example, differs between groups with small and 
large prostate volumes. Consequently, Se and Sp vary according to prostate volume. 
Therefore, diagnostic test characteristics are not a priori generalisable. Possibly
Qmax
non-discriminatory test
perfect test
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because Se and Sp reflect the test results in diseased and non-diseased subjects, there 
is a tendency to select a number of patients and a number of non-patients for 
diagnostic studies. Although suitable for a crude initial assessment of a test’s 
diagnostic value, such a study population is far from optimal. In clinical practice, a 
diagnostic test is used in a population suspected of having the disease (the 
“domain” of the test). Such a population not only includes people who, ultimately, 
clearly have and do not have the disease, but also people with an equivocal 
diagnosis based on uncharacteristic symptoms and tests. Therefore, a clinical 
population will typically yield lower Se and Sp.
The probability of disease in test positive and test negative subjects
Although Se and Sp can certainly be used in the assessment of diagnostic tests, it is 
more logical from a clinical point of view to calculate the probability of disease in 
groups with positive and negative test results. From table 8.1, it can be calculated 
that the probability of having BOO among test positives is 82/115 = 71% and that 
the probability of BOO among test negatives is 18/85 = 21%. These so-called post­
test probabilities can also be calculated using Bayes’ Theorem. The theorem states 
that the post-test odds of disease among test positives are equal to the pre-test odds 
of disease multiplied by the LR+. Likewise, the post-test odds of disease among test 
negatives are equal to the pre-test odds multiplied by LR-. The odds of disease are 
equal to the probability of disease divided by its complement. For instance, from 
table 8.1 it follows that the pre-test probability (prevalence) of having BOO equals 
0.5. The pre-test odds of disease are 0.5/(1-0.5) = 1, the post-test odds among test­
positives are 1*2.5 = 2.5, and the post-test probability is 2.5/3.5 = 71%.
In routine clinical practice, a variety of tests is usually applied to diagnose patients, 
rather than one single test. When several tests must be interpreted, Bayes’ Theorem 
can be applied sequentially by using the posterior probability of one test as the prior 
probability for the next. For this purpose, however, the likelihood ratios of each test 
must be known conditional on all other tests. Consequently, a large number of 
patients is needed to study the likelihoods, as with each additional dichotomous test 
the number of subgroups doubles. Five tests already require 16 subgroups to be 
studied separately. Mathematical models may resolve this problem to some extent.
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Linear regression models calculate the mean value of a variable Y conditional on 
one or more test results. It is constructed from a data set with known values of 
multiple input variables and endpoints. A computer estimates the regression 
coefficients (ß1 ... ßn) that best fit the data.
Y = a + ß1 • test1 +. . .  + ßn • testn linear regression model
Logistic regression models can be used to estimate the probability (prevalence) of 
disease given the results of several diagnostic tests, while accounting for their 
mutual dependencies. Logistic regression models are used because of their property 
to restrict the occurrence of the dependent variable within the stochastic values of 
zero and one. It is possible to identify those tests that do and those that do not help 
to predict the presence of disease. Logistic regression analysis makes no use of 
characteristics like Se or Sp and there is no need to define cutoff points. It is 
possible to calculate a parameter similar to the AUC of ROC-curves, called the C- 
index [Harrell, 1996]. The C-index, just like the AUC, can be used to compare the 
diagnostic value of various models.
P(Y) = l + e-(a+ß1 J t ,  +...+ß„•.«„) lo8istic regression model
Using regression models, the shape of the relation between variables (diagnostic 
tests) must be known. A relation can for instance be linear, quadratic, or logistic 
and the investigator must learn its shape before he can begin with the actual 
analysis. A visual approach is usually adequate if less than three different diagnostic 
tests are involved. In situations that are more complex, a visual approach is difficult 
and linear relations are frequently assumed. If this assumption is false, it may give 
rise to inconclusive results. Furthermore, regression models have difficulty detecting 
interactions between multiple diagnostic tests. A combination of test results that 
distinguishes diseased from non-diseased subjects may thus remain unnoticed. The 
next chapter 9 describes neural network analysis, which may provide a solution to 
this problem.
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Chapter 9 Neural network analysis
Introduction
Neural network analysis is a mathematical technique that is comparable to 
regression analysis. Similar to regression analysis, it can assimilate a large wealth of 
information from real life patients, but in contrast, neural network analysis does not 
require linearity of the data. In fact, the network provides a framework for 
automatically selecting the appropriate relation between variables. As a result, it is 
able to detect subtle and interesting relations between various parameters and 
desired outcome, which remain unnoticed using regression analysis. A network can 
divide diseased and non-diseased subjects into completely separated classes (figure 
9.1) and it may thus be an attractive alternative to traditional regression analysis.
O diseased 
♦  non-diseased
test 1
Figure 9.1 Illustration o fthe  ability o f neural networks to separate diseased and 
non-diseased subjects by non-linear relations and complex interactions 
between diagnostic test results
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A neural network consists of several interconnected nodes (analogous to biological 
neurons), positioned in layers (figure 9.2). There is one input layer, consisting of all 
diagnostic test results, one output layer representing the gold standard variable, and 
typically one or more hidden layers that are used for computational purposes. The 
investigator determines the number of hidden layers and the number of nodes per 
hidden layer.
Input Hidden Output
(e.g., age, IPSS, Qmax, etc) (e.g., bladder outlet obstruction)
Figure 9.2 Layout o f a three-layered neural network
The value of each input node (diagnostic test) is converted by a transformation 
function and sent through to all nodes in the next layer. The transformation 
function (for instance logistic) can act as a threshold, only producing output if the 
input exceeds an a priori defined value. The threshold further resembles a biological 
neuron, which only fires an action potential if enough neurotransmitter from 
adjacent synaptic junctions has accumulated. Each connection between two nodes 
is represented by a weight factor. Weights are numerical values representing the 
strength of connections between nodes. Each adjacent node computes a weighted 
sum of all received input, converts this weighted sum and sends it through to the
112
next layer. The estimated outcome of the network for a particular patient consists 
of the weighted and transformed sum of the output layer.
When training a neural network, the information of each patient is repeatedly 
presented to the network. The estimated outcome is compared to the true (gold 
standard) outcome and a computer calculates the optimal weight factor for each 
inter-node connection, usually using least squared error or maximum likelihood 
methods. All weights are initially designated small random numbers.
If the data of each patient is presented to the network a large number of times, a 
near perfect prediction of the true outcome may result. Rather than having 
meaningful implications, such a perfect network will probably result from 
overfitting the data. In other words, the generalisabilty of such a perfect network to 
other patient populations is poor (figure 9.3).
O diseased 
♦  non-diseased
test 1
Figure 9.3 Illustration ofthe hazard o f overfitting the training data using neural 
networks. The closed curve interaction detected in the training set (figure 
9.1) is not found in the test set and is therefore ignored.
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To prevent overfitting, the data is divided into a training and a validation set. The 
training set is used to estimate the weights of the network, while the validation set 
is used to prevent overfitting the data in the training set. Subdivisions between 
training and validation sets are generated using bootstrapping [Heskes, 1997]. A 
bootstrap sample is a collection of n patients randomly drawn with replacement 
from the total data set, with n indicating the total number of patients. Some 
patients may occur in the sample more than once. The bootstrap sample is taken to 
be the training set, while patients that do not occur in the training set constitute the 
validation set. Using the weights calculated in the training set, a prediction of the 
outcome is also made for patients in the validation set. Each time the weights are 
adjusted, the error in the training set decreases. If the network starts to overfit the 
data in the training set, the error in the validation set starts to increase. Training of 
the network is stopped at this point.
The resulting network depends on the bootstrap sample, i.e., on the random 
subdivision in training and validation set. Therefore, multiple bootstrap samples are 
taken and the training and validation process is repeated for each sample. The sets 
of weights derived from all samples are averaged. To evaluate the overall 
performance of the neural network, a random sample of the original data is set aside 
to be used as a test set. None of the patients in this test set is used for training or for 
validating and can therefore be considered an external and independent source of 
data. The average set of weights (the mean of all bootstrap samples) is used to 
predict outcome for the patients in this independent test set, and the predicted 
outcome is compared to the observed outcome. We used neural network analysis to 
estimate the grade of BOO based on non-invasive diagnostic tests in patients with 
LUTS.
Methods
We analysed the data of men with LUTS, suggestive of BOO or bladder 
dysfunction, who were referred by their general practitioner or by urologists from 
community hospitals, to the University Medical Centre Nijmegen, the Netherlands 
between January 1992 and September 1998. All patients received routine 
investigation, consisting of medical history taking, digital rectal examination and
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transrectal ultrasonography of the prostate, measurement of serum PSA-level, 
assessment of symptoms and quality of life as listed on the IPSS, uroflowmetry 
including determination of Qmax, VV, and PVR. Each patient underwent PFS, 
which was considered the gold standard diagnostic test. Patients in acute urinary 
retention and patients who previously underwent prostatic treatment were excluded 
from the study.
As recommended by the International Continence Society, the Abrams-Griffiths 
number (AG-number) was calculated to quantify the level of urethral obstruction 
according to AG-number = detrusor pressure at Qmax - 2 * Qmax [Griffiths et al., 
1997]. AG-numbers > 40 cmH2O classify patients as obstructed. Patients with AG- 
numbers < 40 cmH2O are either equivocal or not obstructed. All other diagnostic 
test results plus age of the patient were used as possible predictors of AG-number.
Missing values were replaced using maximum likelihood estimation [Arbuckle, 
1996]. Since neural networks perform better on variables that are normally 
distributed, the diagnostic test results were transformed when necessary, using a 
natural logarithm or square root function and standardised with zero mean and 
standard deviation of one. The post-void residual was divided into two variables: 
one indicating if there was any residual urine and another indicating the actual 
amount of residual urine.
Using the neural network, we estimated AG-numbers for all patients in the test set 
and calculated the absolute difference between observed and predicted outcome. 
The estimated AG-numbers were dichotomised with scores > 40 indicating 
obstruction. Sensitivity and specificity of this diagnostic indicator to indicate BOO 
(true AG-number > 40) were calculated. Because sensitivity and specificity depend 
on the chosen cutoff value in the diagnostic test result, we constructed a ROC- 
curve and estimated the associated AUC [Hanley and McNeil, 1982]. Finally, we 
estimated AG-numbers using a traditional linear regression model, and repeated the 
ROC analyses.
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Results
This study investigated 1903 patients with LUTS. Table 9.1 shows a summary of 
patient characteristics. Fifteen hundred randomly selected patients were used to 
train and validate the network. Fifty bootstrap samples were generated and the 
estimated weights of the 50 sets were averaged. Using the average weights, the AG- 
number was predicted for the 403 patients that constituted the test set.
Table 9.1 Patient characteristics (n=1903)
Mean standard
Centiles
deviation 2.5th 50th 97.5th
Age (years) 64 9 45 64 82
Qmax free flow (ml/s) 11 6 4 10 24
Voided volume (ml) 249 150 72 226 640
Prostate volume (ml) 43 23 16 37 101
Serum PSA (ng/ml) 3 4 0 2 14
Post void residual (ml) 63 103 0 25 350
IPSS (0 - 35) 17 7 4 17 30
Quality of life (0 - 6) 4 1 1 4 6
Abrams-Griffiths number (cmH2O) 40 30 -9 36 110
Table 9.2 Stratification o f patients in the test set according to neural network estimation and pressure-
flow outcome
PFS-outcome
Neural network estimation Obstructed 
(AG-number > 40)
Equivocally/not obstructed 
(AG-number < 40)
total
AG-number > 40 128 64 192
AG-number < 40 62 149 211
Total 190 213 403
AG-number, Abrams-Griffiths number; PFS, pressure-flow study
The median absolute difference between true and predicted AG-number calculated 
was 16 cmH2O (2.5th centile 1; 97.5th centile 69). This difference is large relative to 
the recommended standards indicating presence and absence of BOO of 20 and 40 
cmH2O, respectively. Prostate volume, Qmax, PVR (actual amount) and voided
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volume proved to contribute substantially to the network’s estimation, while 
patient age, serum PSA-level, IPSS and quality of life score seemed less relevant. 
Using cutoff values of 40 cmH2O for both estimated and true AG-number, Se and 
Sp of the network were 67% and 70%, respectively (table 9.2). A linear regression 
model produced identical Se and SP. Using a cutoff value of 20 cmH2O, the Se and 
Sp of the neural network were 95% and 18%, and for the linear regression analysis 
96% and 15%. The ROC-curves of the neural network and the regression analysis 
both had an AUC of 0.76 (standard error = 0.02).
□  truly not obstructed □  truly obstructed
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Figure 9 .4  Histogram o f predicted AG-number, in obstructed and equivocally /  not 
obstructed patients. The three categories are based on the probability o f 
being obstructed, increasing from 9% to 44% to 78%. The percentage of 
patients in each category is 22%, 56% and22%.
The results of the neural network can be used to preclude superfluous PFS. Figure
9.4 shows the distribution of estimated AG-numbers stratified according to final 
diagnosis of obstruction (true AG-number above 40 cmH2O). The probability of 
being obstructed for patients with estimated AG-number below 25 (22% of total 
number of patients) is only 9%. Analogously, the probability of being obstructed
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among patients having an estimated AG-number above 55 (22% of total number of 
patients) is 78%. Accurate grading of obstruction in these two outer categories, 
which comprise 44% of all patients, is not needed, since the probability of being 
obstructed is sufficiently high or low to allow treatment decisions to be made. By 
moving up and down the cutoff values (25 and 55 in this example), it is easy to 
exchange the number of PFS performed for certainty in diagnosis.
Discussion
This study showed that is not possible to accurately estimate the grade of BOO 
based on the currently available non-invasive diagnostic tests. The difference 
between true and predicted AG-number was too large relative to the recommended 
standards of 20 and 40 cmH2O, indicating presence and absence of BOO. The 
AUC of 0.78 also reflects the insufficient accuracy of the neural network 
prediction. The use of a neural network, which is able to identify both linear and 
non-linear relations between diagnostic test results, did not improve the estimation 
of BOO compared to a linear regression model.
A number of drawbacks must be kept in mind when using neural networks. Firstly, 
neural networks provide little understanding of the relations between variables; they 
merely estimate outcome measures. Whereas the parameters in traditional 
regression models have clear interpretations, at this moment the weights of neural 
networks have not, unless very specific transfer functions are used [Duh, 1998]. 
Secondly, in noisy problems (much unexplainable variance) neural networks have a 
tendency to restrict themselves to linear relations. As noisy problems are abundant 
in medical research, the performance of a neural network will often be equal to that 
of linear techniques. Thirdly, the way a network should ideally be designed and 
trained is debated. The investigator must choose the number of hidden layers, the 
number of nodes per layer, the way to optimise the connecting weights and the 
shape of the transfer function. These choices may all influence the performance of 
the network. More research in this field is needed. New types of neural networks 
are being developed, among which so-called genetic adaptive models have shown 
promising results [Tewari, 1998]. Finally, a neural network can detect interesting 
relations, provided these are truly present. Many disease mechanisms are not well
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understood, and a neural network should not be considered a magic tool that 
generates new hypotheses. The investigator must still decide which associations to 
study, and unfortunately, many interesting hypotheses are false.
Neural networks have been evaluated and found useful in diagnosing myocardial 
infarction [Baxt, 1992], predicting cancer survival [Burke, 1994] and evaluating 
pathology specimens [O’Leary, 1992], among many other applications. In addition, 
neural networks have recently appeared in urological literature [Pantazopoulos, 
1998; Wei, 1998]. Tewari [1997] gives an excellent review of the strengths and 
shortcomings of neural networks, also focussing on urological applications.
Three previous studies assessed the correlation between PFS outcome and a 
combination of non-invasive tests. Rosier et al. [1996] and van Venrooij et al. 
[1996] constructed algorithms that correlated with PFS outcome better than any 
individual variable. Madersbacher et al. [1997] used logistic regression models to 
assess whether BOO is predictable by clinical evaluation in patients with LUTS. 
They concluded that prostate volume, PVR and Qmax contribute independently to 
the prediction of obstruction. The study by Madersbacher and colleagues shows 
that patients with prostate volumes greater than 50 ml are almost certain to be 
obstructed, independent of other test results. For the vast majority of patients, 
however, with prostate volume below 50 ml, this probability ranges between 50 and 
65%, which comes close to flipping a coin. These three studies are in agreement 
with our findings, showing a high degree of certainty regarding the presence or 
absence of obstruction in extreme categories (low Qmax, large prostate, high PVR 
versus high Qmax, small prostate, no PVR). PFS may safely be omitted in patients 
in these two categories. The large intermediate group of patients, however, remains 
difficult to diagnose.
PFS combine information on detrusor pressure and urinary flow rate to determine 
urethral resistance. Urinary flow rate is measured non-invasively, but detrusor 
pressure is not, although non-invasive methods are being developed [Griffin, 1996; 
Gleason, 1997]. The correlation between currently used diagnostic tests and 
detrusor pressure is poor, even when assessed with neural networks. Therefore, at 
this moment, accurate non-invasive estimation of PFS outcome is impossible.
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Despite its drawbacks and the fact that neural networks did not show additional 
value over traditional regression analysis in diagnosing men with LUTS, this 
relatively new mathematical technique can find its place in medical science. 
Research questions that do not focus on understanding a specific relation but 
instead on prediction of outcome, can be well addressed with neural networks. In 
addition, data from a large number of subjects is needed for the analysis. Such 
situations are typically present in diagnostic and prognostic research. The ability to 
detect non-linear relations and complex interactions between variables in such 
studies impose a large potential for neural networks.
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Chapter 10 Diagnostic research in ill-defined 
diseases
Introduction
The prevailing methods to study the value of a diagnostic test range from the 
calculation of sensitivity and specificity for a crude initial assessment of the test to 
regression analysis and neural networks to determine the test’s diagnostic power 
conditional on other tests. These methods judge the performance of a test by the 
strength of its correlation with a gold standard test. Unfortunately, many examples 
demonstrate that a gold standard is often missing. Some of these so-called ill- 
defined diseases include Attention Deficit Hyperactivity Disorder, Chronic Fatigue 
Syndrome, Sudden Infant Death Syndrome, Irritable Bowel Syndrome, Whiplash, 
Rheumatoid Arthritis, Multiple Sclerosis, and Syndrome X.
Previous authors describing methods of diagnostic research actually noted that their 
methods were confined to diseases for which a gold standard exists [Jaeschke et al., 
1994; van der Schouw et al., 1995; Moons et al., 1997]. The eminent 
epidemiologist Miettinen even holds that in case of a missing gold standard it is 
more rewarding to go fishing than to get involved with diagnostic research 
[Miettinen, personal communication]. Still, others described methods to estimate 
the accuracy of diagnostic tests when the true disease state is not known [Hui and 
Walter, 1980; Valenstein, 1990; Faraone and Tsuang, 1994; Hui and Zhou, 1998]. 
In these methods, the unobservable disease state is called a latent class. Although it 
is not possible to observe correlation between test results and disease state, the 
correlation between the results of two or more tests can be calculated. The principle 
of latent class analyses is to use the observable correlations to estimate the 
unobservable ones. A problem of these methods, however, is that they are unable to 
distinguish between alternative diseases in a differential diagnosis. For instance, 
consider a population of patients presenting with dyspeptic symptoms. In each 
patient, several diseases are considered, including gastric carcinoma, peptic ulcer, 
duodenal ulcer, and reflux oesophagitis. W ithout obtaining ultimate proof of the
121
presence of any condition, it is possible to calculate the correlations between various 
diagnostic tests performed in these patients. Based on these correlations between 
test results, latent class analysis may be used to estimate the sensitivities and 
specificities of the various tests and the prevalence of a latent disease. The question 
that presents itself, however, is which latent disease: carcinoma, ulcer, reflux 
oesophagitis, or yet another one. Different investigators may consider different 
diseases. The correlations between the test results that are observed in the patients 
do not depend on the investigator’s ideas. Latent class analysis will thus estimate the 
same prevalence and the same diagnostic value of tests for any conceivable disease. 
Therefore, this method does not provide a solution if multiple underlying 
conditions are considered. As such differential diagnosis is commonplace in medical 
practice, other ways to determine the value of diagnostic tests are needed in the 
absence of a gold standard.
In this chapter, the problem of a missing gold standard is discussed from a 
philosophical point of view. The principles of diagnostic research flow from the 
adopted concept of disease. We argue that the problem of a missing gold standard 
stems from one particular concept called realism. Given an alternative concept, 
called nominalism, a missing gold standard is not a problem for diagnostic research. 
Moreover, we argue that a nominalist perspective of disease unifies diagnosis and 
prognosis into a single concept. Diagnostic tests must be evaluated prognostically, 
they must be judged by their ability to predict the outcome of treatment.
A realist perspective of disease
Realism is the philosophical position that believes in the real existence of universals. 
A universal can be defined as an abstract object or term, which ranges over 
particular things. For instance, the universal term “largeness” ranges over all 
particular large mountains and large persons. Realism applied to medicine holds 
diseases to be real existing entities. The universal term cancer is the true essence of 
cancer that ranges over all particular instances of cancer. A realist perspective of 
disease is present in colloquial speech: patients visiting a doctor want to know 
which disease is causing their symptoms and doctors are trained to treat disease 
[Scadding, 1996].
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The realist considers a gold standard to be a test that describes the true essence of a 
disease as accurately as possible. For instance, isolation of Mycobacterium 
tuberculosis confirms the presence of tuberculosis, hypercortisolism secondary to a 
pituitary tumour identifies Cushing disease, and a finding of malignant prostate 
cells is a proof for the presence of prostate cancer. By contrast, diagnostic tests are 
mere indications of the true presence of disease.
A dichotomous test has diagnostic value if a disease is more common among test­
positives than among test-negatives. The reason that a test result is related to 
disease is that it is either a risk indicator (not necessarily a risk factor) or a 
manifestation of the disease. For instance, the prevalence of lung cancer is higher 
among people with a history of smoking compared to people who never smoked 
(risk indicator) and is higher among men with a coin lesion on chest X-ray than 
among those without such manifestation (figure 10.1). Thus, a history of smoking 
and coin lesions both suggest the presence of lung cancer and their diagnostic value 
must be judged by the correlation with the presence of the disease. Obviously, in a 
realist perspective, problems with diagnostic test evaluation arise if the definite 
disease state remains unknown.
Figure 10.1 Causal chain o f  lung cancer
The view of diseases having risk factors on one side and and manifestations on the 
other is overly simplistic. Consider for instance men with benign prostatic 
hyperplasia (BPH). This microscopic enlargement of the prostate may become 
macroscopically detectable and may continue to obstruct the prostatic urethra, 
which on its turn may lead to lower urinary tract symptoms (LUTS) (figure 10.2).
* Although the focus is on dichotomous tests, the same principles apply to tests with more than two categories 
and to continuous tests.
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In this example, which stands for a host of other examples, it is arbitrary to have 
one of the conditions take precedence as true disease entity and consider the others 
as risk indicators or manifestations. Instead, all conditions are part of the same 
causal chain. A nominalist perspective of disease recognises this subjectivity of 
defining true disease entities.
Figure 10.2 Causal chain o f  lower urinary tract symptoms
A nominalist perspective of disease
Nominalism maintains that only particular things exist. A general term or name 
(Latin: nomen) is applied to individuals that resemble each other, without the need 
of any reference to an independently existing universal. Thus, there is no 
“largeness”, there are only large objects. Likewise, nominalism rejects the idea of 
true disease states. There is no disease, there are only diseased persons. A condition 
such as cancer refers to a set of persons that share a common characteristic, in this 
case the presence of malignant cells. A nominalist makes no distinction between 
“diseases” and diagnostic test results. The presence of malignant cells and that of a 
coin lesion on chest X-ray are both characteristics that define a set of persons. Also, 
BPH, BPE, BOO, and LUTS are defining characteristics of a collection of patients
By rejecting the idea of true disease entities, the nominalist requires alternative 
methods of diagnostic research. In a way, the nominalist finds himself in a similar 
position as a realist lacking a gold standard. The realist does not know the true 
disease state (epistemological); the nominalist does not believe there is a true disease 
state (ontological). Both are unable to judge the value of a test by its correlation 
with the true disease. The nominalist, however, must not only find alternative 
methods of diagnostic research. Since estimating the probability of disease presence 
does not correspond to his concept of disease, he must also reformulate its object.
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No patient classification is useful if it does not influence the medical management. 
For instance, if sputum examination has established the presence of Mycobacterium 
tuberculosis, all patients will be given antibiotic therapy regardless of the result of 
any further diagnostic test. No alternative therapy is available and thus no test can 
provide information that is valuable for medical management of these patients. If 
two competing antibiotic regimens are considered, however, a diagnostic test is of 
value if it identifies patients that will benefit more from one regimen than from the 
other. Therefore, we argue that diagnosis must be evaluated in combination with 
options for treatment.
A test is useful if the percentage responders to treatment A outweighs the 
percentage responders to treatment B in test positives, while for test negatives 
treatment B is more beneficial. In other instances, a diagnostic test is of no value to 
medical practice. Table 10.1 summarises these alternatives. It follows that the 
object of diagnosis is the estimation of the probability of good response to 
treatment (including watchful waiting) conditional on a set of diagnostic tests. This 
object corresponds to a nominalist perspective of disease, since there is no reference 
to a true disease state. It considers diagnostic tests as defining characteristics of a set 
of persons. The nominalist object of diagnosis has clear prognostic implications. In 
fact, a nominalist perspective of disease fuses diagnosis and prognosis into a single 
concept.
Table 10.1 Conclusion criteria to judge the value o f a diagnostic test
Positive test result Negative test result Conclusion
P(response
P(response
P(response
P(response
treat A) > P(response | treat B) 
treat A) < P(response | treat B) 
treat A) > P(response | treat B) 
treat A) < P(response | treat B)
P(response | treat A) > P(response | treat B) no testing
P(response | treat A) < P(response | treat B) no testing
P(response | treat A) < P(response | treat B) perform test
P(response | treat A) > P(response | treat B) perform test
P(response treat A), probability o f good response to treatment A
* Occasionally, a test is not used to guide treatment. For instance, Huntington’s disease cannot be treated, but 
patients may want to change their lifestyle if they find out that they have the genetic predisposition. Similarly, 
HIV infection cannot be treated yet, but infected people may alter their sexual behaviour.
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Figure 10.3 Flowchart o f a randomised controlled trial to study the value of 
diagnostic tests. P(response | treatment A, test +), probability o f good 
response to treatment A  among test positives
A diagnostic test must be judged by its ability to identify groups of persons that 
differ with respect to the most beneficial treatment. Diagnostic research is thus not 
different from identifying prognostic factors in intervention studies. In case of two 
treatments and one dichotomous test, four percentages must be estimated to decide 
whether a test is useful. The probability of response to treatment A among test 
positives, the probability of response to treatment B among test positives, the 
probability of response to treatment A among test negatives, and the probability of 
response to treatment B among test negatives. Valid estimates of these percentages 
can only be obtained by means of follow-up studies, usually in the form of a 
randomised controlled trial (RCT). Figure 10.3 shows a flowchart of a RCT to 
study the value of a diagnostic test. Based on the results of such a trial, the 
probability of response in future patients can be estimated, conditional on 
treatment and test result. If the value of the effect of treatment is vastly different
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between test positives and test negatives it can be concluded that the test is useful 
for medical practice.
The value of a diagnostic test is determined by its ability to predict the response to 
treatment. Therefore, the same test can be useful in one setting and completely 
redundant in another, depending on the available treatment options.* For instance, 
a finding of an irregularly enlarged prostate on rectal examination is useful to a 
general practitioner as it helps him to decide about patient referral. Initially, 
however, he does not need to know about the presence of metastasised prostate 
cells. By contrast, the urologist is interested in the presence of metastases, as it 
determines his treatment decisions. Thus, the level of detail that a general 
practitioner needs is essentially different from the level of detail required by the 
urologist or any other specialist.
The need for RCTs to evaluate diagnostic tests does not stem from any direct 
influence of a test on the response to treatment. Instead, RCTs are needed because 
diagnostic tests are to be judged by their ability to predict treatment outcome. If a 
trial is designed to learn the predictive value of a new diagnostic test while the effect 
of the treatment itself has already been established, many patients will be denied the 
best treatment. Conducting diagnostic RCTs can therefore be unethical. In 
addition, RCTs are usually time-consuming and expensive. An alternative method 
is applied to evaluate screening programs (figure 10.4). For instance, middle-aged 
women are randomised to participate in a breast cancer screening program. One 
group of women receives annual screening. W omen with a positive screening result 
receive early resection of the suspected lesion/ The other women do not receive 
screening and possible malignancies are detected at a later stage by self-examination. 
The effect of screening is evaluated by the difference in mortality from breast cancer 
between both groups. Although suitable to evaluate the screening program as a 
whole, i.e., screening in combination with early intervention, a possible beneficial 
effect cannot be attributed to either screening or intervention. In other words, the 
diagnostic value of the screening instrument (mammography) remains unknown.
* In addition, the value of a test varies according to the characteristics of the population (e.g., general practice 
versus referral hospital) in which the test is applied.
f  In practice, additional tests are applied to decide which lesions to resect.
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Figure 10.4 Flow chart o f a protocol to evaluate the effect o f screening
In some instances, an almost perfectly discriminating characteristic with respect to 
treatment outcome is available. For instance, the presence of Mycobacterium 
tuberculosis virtually guarantees the success of antibiotic agents. Likewise, the 
presence of bladder outlet obstruction in patients with LUTS usually corresponds 
to good response to resection of the prostate. In such instances, it is not required to 
observe patients over time in a RCT in order to learn the discriminating value of a 
new diagnostic test. Instead, the result of the new test can readily be compared to 
the existing perfectly predicting test. This situation corresponds to the traditional 
methods of diagnostic research, which compare the result of a test to a gold 
standard test. This comparison, however, is an ellipsis for comparing the new test 
with treatment outcome. A gold standard test is not a test that perfectly identifies
* In the diagnosis o f LUTS, a gold standard is supposed to be present by means of PFS. The cutoff values to 
define obstruction, however, have been established by analysing the success of TURP treatment in samples of 
men who preoperatively underwent PFS [Abrams and Griffiths, 1979; Schäfer et al., 1989]. Patients that were 
found to benefit from TURP were retrospectively defined to be “obstructed”, while those who were likely to 
remain bothered by their symptoms were called “unobstructed”. Thus, a urodynamic diagnosis of obstruction 
is in fact a prognostic statement about the success of desobstructive treatment.
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disease state, but a test that perfectly predicts treatment outcome. The problem of a 
missing gold standard does not exist in a nominalist perspective of disease. If a 
nominalist makes note of a missing gold standard, he actually refers to a situation in 
which he cannot predict treatment outcome. This lack of knowledge can be 
overcome by observing test-positives and test-negatives in follow-up studies.
In conclusion, diagnostic research should always focus on estimating the probability 
of response to treatment, in the same way as the study of prognostic factors in 
intervention studies does. Only if a perfectly discriminating test with respect to 
treatment outcome is available, this “gold standard” can be used without 
reservation as a proxy for treatment response. In all other cases in which the specific 
value for medical practice of a test is questioned, follow-up studies must be 
conducted, and the probability of response must be estimated conditional on the 
treatment and the test result.
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Appendix
A nominalist perspective of disease leads us to prognostic methods to evaluate 
diagnostic tests. Meanwhile, a realist approach, assuming truly existing disease 
entities remains intuitively attractive. W hat does a realist refer to when talking 
about disease as a truly existing matter of nature? This question proves difficult to 
answer, considering the many discussions about the topic [Boorse, 1977; Hare, 
1986; Margolis, 1986; Merskey, 1986; Nordenfelt, 1986; Emson, 1987; W ulff et 
al., 1990; Scadding, 1996; Davis, 1996]. Diseases are usually distinguished from 
illnesses [Mayou and Sharpe, 1995]. The former relates to an objectively 
identifiable biological malfunction; the latter refers to the feeling of a patient. 
Diseases are likely to correlate with illness, but not necessarily so. A patient with 
prostate cancer is diseased, whether or not he is aware of its existence. Diagnosis 
consists of identifying the pathological agent. The realist view of disease is well 
expressed by Christopher Boorse [1977]: “A disease entity is the state o f an individual 
which interferes with or even prevents the normal function o f some organ or system o f  
organs belonging to the bearer ofthe state. The normal function is based on the species 
design for man. ” This perspective is also referred to as essentialist, biostatistical, and 
atomistic-biological.
The most important feature of the realist perspective is the normal function. We 
have to be familiar with the normal functions of organs and systems of organs in 
order to make judgements about disease. How do we decide which functions are 
physiological and which are pathological? According to Boorse, the normal 
functions of the body are laid down in the species design. The species design is the 
ideal form of the human body. It is Plato’s ideal, universal, and unchanging man. 
The normal function of each organ is fixed, just like the brakes of an automobile. 
There is, however, an important difference between a human being and an 
automobile, in that we designed the latter with a specific goal in mind. This goal 
can be described as quick, safe, and comfortable transportation. All parts of a car 
are instrumental to the overall goal and it is therefore relatively easy to judge 
whether a part of the car functions normally. By contrast, we did not design the 
human species, nor do we know its goals. Therefore, it is impossible to judge about 
normal function of a human organ.
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It is often argued that the function of our organs is not questionable at all. We use 
our eyes to see, our lungs to exchange gas, and our heart to pump oxygenated blood 
to the cells of the body. If the heart fails to provide adequate circulation of blood, it 
is diseased. Along the same lines, Boorse tries to circumvent the need to know the 
goals of the human body by reverting to statistics: “Normal functioning is the 
performance by each internal part [of the body] with at least statistically typical 
efficiency. ” He argues that every function of every organ must be measured 
separately in a large number of people and normal values must be calculated. The 
mean values of these calculations correspond to the normal functions as laid down 
in the species design. The presence of disease can be identified by a deviation from 
the m ean/
A statistical approach, as Boorse proposes, is certainly helpful. It is not sufficient, 
however, to judge about the normal function of organs or systems of organs: if a 
group of Martian doctors were to examine the function of the lower urinary tract in 
a group of ageing human males and reason according to Boorse’s ideas, they are 
likely to conclude that the function of the prostate is to prevent urine to pass the 
urethra. They would reach this conclusion by observing that the prostate obstructs 
the bladder outlet in the majority of elderly men. Subsequently, they might 
conclude that large prostates are physiological while small prostates are 
pathological. Why is it that we do accept circulation of blood as function of the 
heart and we do not accept blockage of urine as function of the prostate? 
Statistically speaking, both occur in the majority of elderly men. The reason for this 
duality is that we implicitly assume one or more overall goals of the human 
organism. Provided we value prolongation of life, we can reason that it is important 
to have circulation of blood and to loose urine. An enlarged prostate, although very 
common, is therefore abnormal. The point is that we need to define one or more 
goals of the human life to judge about normal functions of organs, and 
consequently, to judge about the presence of disease.
* Adolphe Quetelet (1796-1874) also came to think of "average" physical and mental qualities and presented his 
conception of l ’homme moyenne (the average man) as the central value about which measurements of a 
human trait are grouped. The body mass index, which is still frequently used to quantify obesity, is just one of 
the characteristics that Quetelet documented.
f  The popular use of reference ranges for interpreting clinical laboratory tests is based on this statistical 
approach of disease. Reference values are usually set to include 95% of the population, although any threshold 
is clearly chosen arbitrarily.
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According to Boorse, disease is a cause of abnormal functioning. If we accept that 
normal functioning depends on the ability to achieve goals, it follows that disease is 
a cause of not being able to achieve one’s goals. As the realisation of our goals takes 
place in the future, the ultimate proof about the presence of disease also lies in the 
future. In other words, in a realist perspective, like in a nominalist perspective, 
disease has prognostic implications. If we want to know whether a diagnostic test is 
related to the realist’s view of disease, we want to know if it can predict whether a 
person will be able to achieve his goals. This type of questions requires follow-up 
studies, unless a perfect predictor is already available.
* The goals of human life are often approached from an evolutionary point of view. It is argued that since 
mankind has evolved by improving survival and reproduction, each organ or system of organs ultimately helps 
to preserve and propagate human life. We must be cautious, however, to infer from the theory of evolution that 
the goals of an individual person are also restricted to survival and reproduction. This approach would 
underestimate our self-awareness, our capacity for self-reflection and, perhaps most importantly, our ability to 
decide for ourselves what is important in life [Wulff et al., 1990].
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Summary
This thesis addressed the object and methods of diagnostic test evaluation, 
focussing on the diagnosis of men with Lower Urinary Tract Symptoms (LUTS). 
Part 1 served as an introduction to this ill-defined disease. In chapter 1, the relation 
between benign prostatic hyperplasia (BPH), benign prostatic enlargement and 
bladder outlet obstruction (BOO) in the aetiology of LUTS was explained. These 
conditions can be present without causing symptoms. Therefore, diagnosis in men 
with LUTS can be difficult. In addition, the first chapter described the current 
diagnostic tests and therapies.
Chapter 2 presented descriptive statistics on LUTS from the Dutch part of an 
international, population-based study on the epidemiology of urological conditions. 
A fifth of all Dutch men have moderate to severe symptoms. The prevalence 
increases with age: 10% of men aged 40-49 report moderate to severe symptoms 
compared to 21% of men aged 50-59, 33% of men aged 60-69 and 44% of men 
aged 70-79. Dribbling, reduced force of stream and urgency are the most prevalent 
symptoms. While disease specific quality of life (QoL) is moderately related to the 
presence of urological symptoms, generic QoL is virtually independent of 
symptoms. Seven percent of all men visited a doctor because of LUTS in the past 
six months. Six percent of these patients were prescribed prostate-related 
medication. As much as 30% of men with severe symptoms or reduced disease- 
specific QoL does not seek medical attention. In conclusion, LUTS are common in 
the Dutch male population, but the impact on QoL is not pronounced.
In chapter 3, the literature on the aetiology of BPH was reviewed. Increasing 
knowledge about risk factors is of importance to diagnosis, as each risk factor can 
be used to distinguish between those with and those without the disease. 
Epidemiological studies reveal little evidence of an increased risk of BPH due to 
smoking. Obesity may be associated with prostatic enlargement, but firm evidence 
for a relation with symptoms or obstruction is lacking. Positive family history does 
appear to be related to BPH, although a genetic predisposition has not yet been 
discovered. A new hypothesis on the aetiology of BPH involves the so-called 
metabolic syndrome. This syndrome may link several suggested causative factors in
147
the development of BPH, including obesity and hypertension, to a common entity. 
Still more research into the aetiology of BPH is warranted. Several methodological 
limitations face aetiological studies on BPH. It must therefore be assured that the 
expected outcome of a study justifies the associated efforts and costs.
Part 2 of the thesis covered issues of reproducibility. Multilevel regression analysis 
was described, which can be used to quantify the total variation of repeated 
measurements, specific variance components and the effect of known sources of 
variation. These methods can be applied to any field of (medical) research. For 
instance, changes in blood pressure, bone mass density, expiratory volume, and 
tumour markers can be studied with these methods. In addition, multilevel analysis 
is useful in aetiological research with time varying exposure or endpoints. Chapter 4 
described a study on the variability in maximum urinary flow rate (Qmax) in men 
with LUTS. Using a home-based portable uroflowmeter, an average of ten flow 
measurements from over 200 patients was collected. The average coefficient of 
variation (CV) in Qmax of these patients was 27%. This finding shows that a single 
Qmax measurement of a patient may deviate 2 * 27% = 54% from the mean Qmax 
of that patient. To allow a 10% deviation from the true mean Qmax (e.g. 15 ml/s ±
1.5 ml/s), 25 flow measurements are necessary. The conclusion was that a single 
Qmax measurement, as is usually obtained in urological practice, is of limited 
clinical value.
One of the reasons for the large variability in Qmax is its dependence on voided 
volume (VV). Accounting for the relation with VV reduces the within patient 
variability in Qmax. In general, patients with BOO have lower Qmax and lower 
VV compared to men presenting with LUTS due to other causes. Adjusting Qmax 
for VV must not reduce this heterogeneity in Qmax between patients, as it can be 
used to distinguish between various causes of LUTS. Any type of adjustment for 
VV must therefore be made at an individual level, not at a population level. 
Previously developed methods to adjust for the volume dependency, such as the 
Siroky nomogram and Von Garrelts’ square root adjustment, did not acknowledge 
this problem. In chapter 5, we described whether reduction of the variability in 
Qmax is possible without affecting the heterogeneity in Qmax between patients. 
We performed multilevel regression analysis with the same data used to estimate the 
variability in Qmax in chapter 4. In agreement with most previous studies, we
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found a clear hyperbolic relation according to Qmax = 2.4 * VV025. Adjustment for 
VV involves a 30% reduction of the within patient variability in Qmax. The slope 
of the regression line relating VV to Qmax, however, differed substantially across 
patients. It is therefore inappropriate to use a common method of adjustment for 
all patients. The only valid option, albeit impractical, is to calculate an individual 
regression line for each patient based on repeated uroflow measurements.
A pressure-flow study is the gold standard diagnostic test to detect BOO. The 
Abrams-Griffiths (AG) number is calculated from pressure-flow studies (PFS) to 
quantify the grade of obstruction. AG-numbers above 40 indicate obstruction, AG- 
numbers between 20 and 40 are equivocal, and AG-numbers below 20 suggest the 
absence of obstruction. If obstruction is established, resection of the prostate is 
indicated. In chapter 6, we assessed the variability of AG-number in 89 men with 
LUTS within a four-week test-retest interval. By choosing a short period between 
two consecutive PFS, but notably not performing two tests within a single session, 
both tests represent the same routine testing procedure. A retest within the same 
session of testing does not allow the detrusor muscle to regain strength, while 
stretch receptors in the bladder wall may become less sensitive to filling. 
Furthermore, factors that are related to the outcome of PFS are more similar within 
a single session than between visits. Alternatively, a retest 26 weeks or more after 
the initial test cannot preclude systematic changes in urethral resistance or detrusor 
contractility. We found an average within patient standard deviation (SD) in AG- 
number of 14 cmH2O. This finding shows that if a patient’s AG-number is 30 at 
the first visit, his true AG-number can be any value between 30 ± 1.96 * 14 = 3 to 
57, due to random variability alone. Thirty-nine percent of the patients changed at 
least one category of obstruction at the second visit and 3% changed from definitely 
obstructed to definitely unobstructed or vice versa. Based on the large within 
patient variability, we concluded that PFS cannot meet the criteria for serving as a 
gold standard to identify BOO in patients with LUTS.
Discrepancies in the interpretation of PFS recordings between physicians and 
between repeated readings by the same physician may be responsible for part of the 
variation in PFS. In chapter 7, we assessed the within and between observer 
variation in the interpretation of PFS. Photocopies of 200 PFS prints were analysed 
manually by six experienced urodynamicists, with determination of the AG-
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number. Afterwards all 200 PFS were analysed again in a different order. Using 
multi-level regression analysis, we estimated the within and between observer 
variability in AG-number. The within observer SD was 3.7 cmH2O. The between 
observer standard deviation (SD) was 10.0 cmH2O. The combined within and 
between observer SD was 10.7 cmH2O. This latter estimate implies that the 
difference between the estimated AG-number of a single PFS by two observers can 
be as large as 30 cmH2O. Given the advised cutoffs in AG-number of 20 and 40 
cmH2O to indicate the absence and presence of obstruction, we concluded that the 
interpretation of the physician has much influence on the result of PFS. 
International standards on the interpretation of PFS and high-quality education of 
new urodynamicists according to these guidelines are important means for 
improving the interpretation of PFS.
Part 3 of this thesis dealt with the object and methods of diagnostic research. 
Traditionally, the object of diagnostic research is defined as the estimation of the 
prevalence of a disease conditional on a set of diagnostic test results. Chapter 8 
described the traditional methods used to evaluate diagnostic tests, ranging from 
the calculation of sensitivity and specificity to likelihood ratios, ROC-curves, and 
regression analysis. Logistic regression is considered the proper theoretical 
framework for diagnosis and diagnostic research. A drawback of regression models, 
however, is that they have difficulty detecting non-linear relations and complex 
interactions between two or more variables. Chapter 9 described neural network 
analysis, which can provide a solution for these problems. Neural network analysis 
is a mathematical technique that provides a framework for automatically selecting 
the appropriate relation between variables. We evaluated the performance of a 
neural network to detect BOO in 1903 patients presenting with LUTS. Nine non­
invasive diagnostic tests were used as input for the network. A linear regression 
model produced identical results. The median absolute difference between true and 
predicted AG-number was 15 cmH2O. This difference is large relative to the 
recommended standards indicating presence and absence of BOO of 20 and 40 
cmH2O, respectively. Despite the inability of neural network analysis to accurately 
predict the grade of BOO, this method can be useful in medical research. The 
parameters of neural network have no clear interpretation. Therefore, diagnostic 
and prognostic studies, in which the focus is not so much on understanding the
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relation between variables, but on outcome prediction instead, are particularly 
suitable to be evaluated with the use of neural network analysis.
The traditional object of diagnostic research is the estimation of the prevalence of 
disease. Problems with diagnostic test evaluation will thus arise if the current state 
of medical knowledge does not permit measurement of the true disease state, i.e., if 
a gold standard is missing. In chapter 10, the problem of a missing gold standard 
was discussed from a philosophical point of view. It was argued that the traditional 
methods of diagnostic research as described in chapters 8 and 9 are based on a 
realist perspective of disease. A realist holds diseases to be matters of nature, existing 
irrespective of human thought. Diagnosis consists of identifying the true disease 
entity. Alternatively, a nominalist perspective holds diseases to be conventions of 
the human mind, used to structure our perception of nature. Nominalism rejects 
the idea of true disease states. There is no disease; there are only diseased persons. A 
nominalist does not distinguish between diseases and diagnostic tests; both are used 
to classify persons. By rejecting the idea of a true disease entity, the nominalist 
needs an alternative object of diagnosis and consequently he needs different 
methods of diagnostic research as well. Given that a patient characteristic is useful 
to clinical practice only if it classifies patients with respect to treatment response, a 
diagnostic test must be judged by its ability to predict the outcome of treatment 
(including watchful waiting). Consequently, diagnostic test evaluation requires 
follow-up studies, frequently in the form of randomised controlled trials. A 
diagnostic test can occasionally be compared to another test, if the latter is known 
to have excellent predictive ability with respect to treatment outcome. This 
situation corresponds to the traditional method of diagnostic research. The 
comparison, however, is an ellipsis for comparing the new test with treatment 
outcome. In a nominalist view, diagnostic research is no different from identifying 
prognostic factors in intervention studies. Thus, a nominalist perspective of disease 
unifies diagnosis and prognosis into a single concept. The traditional gold standard 
test does not perfectly identify the disease state, but perfectly predicts treatment 
outcome instead. A missing gold standard test is therefore not a drawback for 
diagnostic research.
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Samenvatting
Dit proefschrift behandelde het doel en de methoden van diagnostisch onderzoek 
toegepast op de diagnostiek van lagere urinewegsymptomen (lower urinary tract 
symptoms, LUTS). Het eerste deel van het proefschrift gaf een introductie op 
LUTS. In hoofdstuk 1 kwam de relatie tussen benigne prostaathyperplasie (BPH), 
benigne prostaatvergroting en blaasuitgang obstructie (bladder outlet obstruction, 
BOO) aan bod. Deze drie aspecten spelen vaak een rol in het ontstaan van LUTS, 
maar kunnen ook symptoomloos aanwezig zijn. Diagnostiek bij mannen met 
LUTS is dan ook vaak niet eenduidig. De huidige diagnostische tests en 
behandelmethoden werden tevens in dit hoofdstuk besproken.
In hoofdstuk 2 presenteerden we de Nederlandse resultaten van een internationale 
studie naar de prevalentie van LUTS. Een vijfde deel van alle Nederlandse mannen 
heeft matige tot ernstige LUTS. De prevalentie neemt toe met de leeftijd, van 10% 
onder mannen van 40-49 jaar, 21% onder mannen van 50-59 jaar, 33% onder 
mannen van 60-69 jaar en 44% onder mannen tussen 70-79 jaar oud. 
Nadruppelen, afgenomen kracht van de urinestraal, en sterke aandrang zijn de 
meest voorkomende symptomen. Ziektespecifieke kwaliteit van leven (KvL) neemt 
weliswaar af met toenemende ernst van symptomen, maar de invloed van 
symptomen op de algemene KvL is gering. Zeven procent van alle mannen heeft de 
afgelopen zes maanden een arts bezocht in verband met LUTS. Zes procent hiervan 
kreeg medicatie om de obstructie van de prostaat op te heffen. Echter, maar liefst 
30% van de mannen met matige of ernstige symptomen heeft daarvoor geen 
medische hulp gezocht. Concluderend komen LUTS veel voor bij Nederlandse 
mannen, maar de invloed van symptomen op de KvL is beperkt
In hoofdstuk 3 werd de literatuur over risicofactoren voor BPH / LUTS 
samengevat. Etiologische kennis is van belang voor diagnostiek, omdat bekende 
risicofactoren gebruikt kunnen worden om zieken van niet zieken te onderscheiden. 
Epidemiologische studies geven weinig aanwijzingen voor een causale rol van roken 
in het ontstaan van BPH. Overgewicht lijkt wel te zijn geassocieerd met een 
verhoogd risico op prostaat vergroting, maar er is geen duidelijk verband met symp­
tomen en obstructie. De aanwezigheid van familieleden met BPH geeft een
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verhoogd risico, hoewel er geen specifiek overervingmechanisme voor deze 
predispositie bekend is. Een nieuwe hypothese over het ontstaan van BPH houdt 
verband met het metabole syndroom X. Dit syndroom kan mogelijk enkele eerder 
veronderstelde risicofactoren zoals overgewicht en hoge bloedruk onder een zelfde 
noemer plaatsen. Ondanks de vele onderzoeken, is nog altijd weinig bekend over 
het ontstaan van BPH. Meer onderzoek is dan ook op zijn plaats. Bij nieuw op te 
zetten studies moet echter uitdrukkelijk stil worden gestaan bij enkele 
methodologische problemen die etiologisch onderzoek naar BPH bemoeilijken. 
Voor elke studie moet worden nagegaan of de inspanningen en kosten betekenis­
volle resultaten kunnen opleveren.
Deel twee van dit proefschrift behandelde de reproduceerbaarheid van 
diagnostische tests. Multilevel regressieanalyse werd gebruikt om de variatie in 
herhaalde metingen van een test te kwantificeren. Deze methoden kunnen ook 
worden gebruikt om specifieke variantie componenten te bepalen van bijvoorbeeld 
bloeddruk, botdichtheid, long volumina en tumor markers. Tenslotte kunnen 
multilevel analyses worden toegepast in etiologisch onderzoek met in de tijd 
variërende expositie niveaus. In hoofdstuk 4 bestudeerden we de variatie in 
maximale urinestroom (Qmax) in mannen met LUTS. Meer dan 200 patiënten 
gebruikten een draagbare urineflowmeter en registreerden gemiddeld tien metingen 
per persoon. De gemiddelde variatie coëfficiënt (CV) was 27%. Dit houdt in dat 
een eenmalig gemeten Qmax 2 * 27% = 54% kan afwijken van de gemiddelde 
Qmax van de betreffende patiënt. Bij een maximale afwijking van 10% (b.v. 15 
ml/s ± 1,5 ml/s), zijn 25 metingen noodzakelijk. Samenvattend levert een 
eenmalige Qmax bepaling zoals gebruikelijk is in de urologische praktijk weinig 
zinvolle informatie op.
Een oorzaak voor de grote variatie in Qmax is de relatie met het geplaste volume 
(voided volume, VV). Correctie voor VV kan de variatie in Qmax binnen patiënten 
verminderen. Het geplaste volume heeft zelf echter ook diagnostische waarde: 
patiënten met BOO hebben in het algemeen een lager VV dan patiënten met 
LUTS door andere oorzaken. Correctie van Qmax voor VV moet de heterogeniteit 
tussen patiënten niet reduceren. Bij de ontwikkeling van enkele veel gebruikte 
methoden voor volume aanpassing, zoals de “vierkantswortel aanpassing” volgens 
Von Garrelts en de Syroki nomogrammen is voorbij gegaan aan het boven
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beschreven probleem. In hoofdstuk 5 bestudeerden we met behulp van multilevel 
regressieanalyses de relatie tussen Qmax en VV. Net als in vorige studies was er een 
hyperbole relatie volgens Qmax = 2,4 * VV0,25. Volume verklaarde 30% van de 
variatie in Qmax. De index 0,25 is een gemiddelde van alle patiëten. De waarde van 
deze index wisselde echter sterk tussen patiënten. Het is daarom onjuist om voor 
elke patiënt een zelfde formule te gebruiken om Qmax te corrigeren. De enige 
valide oplossing, die echter praktisch moeilijk uitvoerbaar is, is om voor iedere 
patiënt een individuele regressielijn te bepalen op basis van herhaalde metingen.
Een pressure-flow studie (PFS) wordt beschouwd als de gouden standaard om 
BOO mee aan te tonen. Aan de hand van PFS wordt het Abrams-Griffith (AG) 
nummer berekend. AG-nummers boven 40 cmH2O duiden op obstructie, AG- 
nummers onder de 20 cmH2O geven afwezigheid van obstructie aan. Een diagnose 
van obstructie geeft vaak aanleiding tot resectie van de prostaat. In hoofdstuk 6 
hebben we de variatie bepaald in het AG-nummer door 89 mannen twee keer een 
PFS te laten ondergaan. De tweede test vond altijd plaats binnen vier weken na de 
eerste test, maar nooit op dezelfde dag. Hierdoor zijn systematische verschillen, 
zoals groei van de prostaat en vermoeidheid van de detrusor spier, zo goed mogelijk 
voorkomen. Bovendien zouden enkele bronnen van variatie, zoals circadiane ritmes, 
worden uitgeschakeld door twee metingen direct na elkaar. Dit zou kunnen leiden 
tot een onderschatting van de werkelijke variatie. In ons onderzoek bedroeg de 
standaard deviatie (SD) in het AG-nummer van een individuele patiënt 14 cmH2O. 
Dit betekent dat wanneer een AG-nummer van bijvoorbeeld 30 cmH2O wordt 
gemeten dat het ware gemiddelde AG-nummer kan liggen in het interval 30 ± 1,96 
* 14 = 3 tot 57 cmH2O. Negenendertig procent van de patiënten wisselde van 
obstructiecategorie tussen de metingen. Drie procent wisselde van absoluut 
obstructief naar absoluut niet obstructief of andersom. Wij concludeerden dat door 
de grote toevalsvariatie, urodynamisch onderzoek in de praktijk niet te gebruiken is 
als gouden standaard bij mannen met lagere urinewegsymptomen.
Een mogelijke bron van variatie in PFS is de interpretatie van het onderzoek door 
de arts. Zowel tussen artsen onderling als tussen herhaalde beoordelingen van 
dezelfde arts kunnen verschillen bestaan. In hoofdstuk 7 hebben we stil gestaan bij 
verschillen in de interpretatie van PFS. Aan zes urodynamisch geschoolde artsen 
werd gevraagd om van 200 PFS in duplo het AG-nummer te bepalen. Met behulp
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van multilevel regressieanalyses berekenden we de tussen en binnen beoordelaar 
varianties in AG-nummer. De SD tussen beoordelaars was 3,7 cmH2O, de SD 
binnen afzonderlijke beoordelaars was 10,0 cmH2O. Gecombineerd geeft dat een 
SD van 10,7 cmH2O. De interpretatie hiervan is dat het verschil in AG-nummer 
van dezelfde PFS tussen twee beoordelaars 30 cmH2O kan bedragen. De 
interpretatie van de arts blijkt dus een zeer grote invloed te hebben op de 
uiteindelijke “gouden standaard” diagnose van de patiënt. Een gedegen opleiding 
voor toekomstige urodynamisch georiënteerde artsen en nascholingen om eventueel 
ingeslopen fouten te corrigeren zouden de interpretatie van PFS kunnen verbeteren.
Het derde deel van dit proefschrift behandelde het doel en de methoden van 
diagnostisch onderzoek. Traditioneel wordt het doel van diagnostiek gedefinieerd 
als het schatten van de prevalentie van ziekte, als functie van één of meer 
testuitslagen. In hoofdstuk 8 werden de gebruikelijke methoden van diagnostisch 
onderzoek beschreven, zoals de berekening van sensitiviteit en specificiteit, ROC- 
curves, likelihood ratio’s en regressieanalyse. Logistische regressieanalyse wordt 
veelal gezien als de beste methode om diagnostische tests te beoordelen. Regressie 
analyse heeft echter problemen met het analyseren van niet-lineaire verbanden 
tussen variabelen en van hogere orde interacties. In hoofdstuk 9 werden neurale 
netwerken besproken, die een oplossing kunnen bieden voor deze problemen. Een 
neuraal netwerk is een wiskundige model dat zelf de meest passende relatie tussen 
variabelen bepaalt. Wij gebruikten een neuraal netwerk om de uitkomst van PFS te 
voorspellen op basis van niet invasieve diagnostische test uitslagen. De 
diagnostische informatie van 1903 patiënten met LUTS werd gebruikt voor de 
analyse. Het mediane absolute verschil tussen voorspelde en werkelijk AG-nummer 
was 15 cmH2O. Afgezet tegen de obstructie afkappunten van 20 en 40 cmH2O, 
concludeerden we dat de voorspelling van het neuraal netwerk onvoldoende 
nauwkeurig is om beslissingen over behandeling op te baseren. De resultaten van 
een lineaire regressieanalyse waren vrijwel identiek aan die van het neurale netwerk. 
Ondanks de weinig belovende resultaten van een neuraal netwerk in deze studie, 
kan deze methode zijn waarde bewijzen voor medisch onderzoek. De parameters 
van een neuraal netwerk hebben geen duidelijke betekenis. Daarom zullen neurale 
netwerken met name in diagnostisch en prognostisch onderzoek zinvol blijken te 
zijn, omdat in dit type onderzoek de specifieke relaties tussen variabelen minder van 
belang zijn dan de voorspellende waarde van het model.
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Gezien het traditionele doel van diagnostiek, te weten het schatten van de kans op 
ziekte, doen zich problemen voor met de evaluatie van diagnostische tests indien de 
aanwezigheid van ziekte niet met zekerheid kan worden bepaald, met andere 
woorden indien een gouden standaard ontbreekt. In hoofdstuk 10 werd het 
probleem van een ontbrekende gouden standaard bekeken vanuit een filosofisch 
perspectief. De huidige methoden van diagnostisch onderzoek, zoals beschreven in 
de hoofdstukken 8 en 9, zijn terug te voeren op een realistisch beeld van het 
concept ziekte. Een realist ziet ziekten als werkelijk bestaande entiteiten, die 
onafhankelijk zijn van menselijke perceptie. Diagnostiek is het aantonen van de 
werkelijke essentie van de ziekte. Een andere invulling van het concept ziekte komt 
voort uit het nominalisme. Volgens het nominalisme verwijst ziekte niet naar een 
werkelijk bestaande essentie, maar naar een verzameling mensen met 
overeenkomstige kenmerken. Verzamelingen zijn het product van menselijk 
denken, we gebruiken ze om structuur aan te brengen in onze observaties. Er zijn 
geen ziekten, er zijn louter zieke mensen. Het nominalisme maakt geen onderscheid 
tussen “ziekten” en diagnostische test uitslagen. Het verwerpen van ware ziekte 
entiteiten noodzaakt de nominalist tot het definiëren van een alternatief doel en 
bijgevolg ook andere methoden van diagnostisch onderzoek. We beargumenteerden 
dat een test alleen zinvol is wanneer op basis van de testuitslag het resultaat van 
behandeling voorspelt kan worden. De evaluatie van een test kan daarom niet los 
worden gezien van behandelingsresultaat. Voor test evaluatie is dus longitudinaal 
onderzoek noodzakelijk, gewoonlijk in de vorm van een gerandomiseerde trial. 
Alleen in het geval dat een bestaande test perfect correleert met behandelings­
resultaat, is een gerandomiseerde trial niet nodig. Het resultaat van een nieuwe test 
kan dan worden vergeleken met dat van de al aanwezige test. Deze methode komt 
overeen met het traditionele diagnostische onderzoek waarbij een test wordt 
vergeleken met een gouden standaard. De gouden standaard is dan een surrogaat 
voor het behandelingsresultaat. In een nominalistische benadering van het begrip 
ziekte fuseren diagnostiek en prognostiek tot één concept. Concluderend komt de 
evaluatie van diagnostische tests overeen met het onderzoek naar prognostische 
factoren in interventie studies. Een gouden standaard is niet een test die perfect de 
aan- en afwezigheid van ziekte aantoont, maar een test die perfect het resultaat van 
behandeling voorspelt. Een ontbrekende gouden standaard is geen principieel 
probleem voor diagnostische onderzoek.
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List o f abbreviations
AG-number Abrams-Griffiths number
AUC Area Under the Curve
BII BPH Impact Index
BMI Body Mass Index
BOO Bladder O utlet Obstruction
BPE Benign Prostatic Enlargement
BPH Benign Prostatic Hyperplasia
CI Confidence Interval
CV Coefficient ofVariation
D H T DiHydroTestosterone
ICS International Continence Society
IPSS International Prostate Symptom Score
L Q Natural logarithm o f maxim urinary flow rate
LR- Likelihood Ratio o fa  negative test
LR+ Likelihood Ratio o fa  positive test
LUTS Lower Urinary Tract Symptoms
LV Natural logarithm ofvoided volume
MCS Mental Component Score
PCS Physical Component Score
pdetQmax Detrusor pressure at maximum urinary flow rate
P-flow Portable uroflowmeter
PFS Pressure Flow Studies
PSA Prostate Specific Antigen
PVR Post-Void Residual urine
Qmax Maximum urinary flow rate
QoL Quality ofLife
RCT Randomized Controlled Trial
ROC Receiver Operating Characteristic
RR Risk Ratio
SD Standard Deviation
Se Sensitivity
Sp Specificity
T U M T TransUrethral Microwave Thermotherapy
TURP TransUrethral Resection of the Prostate
URA Urethral resistance index
VV Voided Volume
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